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ABSTRACT 
 
RACHEL HUXFORD PHILLIPS:  Nanoscale Coordination Polymers for Anticancer Drug 
Delivery 
(Under the direction of Wenbin Lin) 
 
 
 This dissertation reports the synthesis and characterization of nanoscale coordination 
polymers (NCPs) for anticancer drug delivery. Nanoparticles have been explored in order to 
address the limitations of small molecule chemotherapeutics. NCPs have been investigated as 
drug delivery vehicles as they can exhibit the same beneficial properties as the bulk metal-
organic frameworks as well as interesting characteristics that are unique to nanomaterials.  
 Gd-MTX (MTX = methotrexate) NCPs with a MTX loading of 71.6 wt% were 
synthesized and stabilized by encapsulation within a lipid bilayer containing anisamide (AA),  
a small molecule that targets sigma receptors which are overexpressed in many cancer 
tissues. Functionalization with AA allows for targeted delivery and controlled release to 
cancer cells, as shown by enhanced efficacy against leukemia cells. The NCPs were doped 
with Ru(bpy)32+ (bpy = 2,2’-bipyridine), and this formulation was utilized as an optical 
imaging agent by confocal microscopy.  
NCPs containing the chemotherapeutic pemetrexed (PMX) were synthesized using 
different binding metals. Zr-based materials could not be stabilized by encapsulation with a 
lipid bilayer, and Gd-based materials showed that PMX had degraded during synthesis. 
However, Hf-based NCPs containing 19.7 wt% PMX were stabilized by a lipid coating and 
iv 
 
showed in vitro efficacy against non-small cell lung cancer (NSCLC) cell lines. Enhanced 
efficacy was observed for formulations containing AA.  
Additionally, NCP formulations containing the cisplatin prodrug disuccinatocisplatin 
were prepared; one of these formulations could be stabilized by encapsulation within a lipid 
layer. Coating with a lipid layer doped with AA rendered this formulation an active 
targeting agent. The resulting formulation proved more potent than free cisplatin in NSCLC 
cell lines. Improved NCP uptake was demonstrated by confocal microscopy and competitive 
binding assays. 
Finally, a Pt(IV) oxaliplatin prodrug was synthesized and incorporated in different 
NCPs using various binding metals. A moderate drug loading of 44.9 wt% was determined 
for Zr-based NCPs. This drug loading, along with a diameter less than 200 nm, make these 
particles promising candidates for further stabilization via lipid encapsulation. 
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CHAPTER 1 
 
An Overview of Anticancer Chemotherapy with Nanoscale Coordination Polymers 
 
(Portions of this chapter were adapted with permission from Huxford, R.C.; Della Rocca, J.; 
Lin, W. Curr. Opin. Chem. Biol. 2010, 14, 262. Copyright 2010 Elsevier) 
 
 
1.1. Introduction  
Despite remarkable progress in the fundamental biology behind many diseases, we 
have yet to achieve comparable advances in the treatment of these diseases, particularly 
cancer. Current therapeutics, small molecule drugs, are limited by their nonspecific 
distribution throughout the body and rapid clearance, resulting in poor pharmacokinetics, 
high doses, high side effects, and narrow therapeutic windows.1,2 In the effort to alleviate 
these drawbacks of small molecule chemotherapeutics, nanoparticle-based therapeutics have 
received an increasing amount of attention over the past 25 years. These novel systems are 
typically composed of an active agent (e.g., chemotherapy drug or prodrug) incorporated 
within the nanoparticle carrier. A variety of nanocarriers have been designed for this purpose, 
such as polymeric nanoparticles, micelles, liposomes, iron oxide, and gold.3,4 Nanomaterials 
display several beneficial characteristics that make them adept at drug delivery such as small 
size, high drug loadings, surface functionality, favorable drug release kinetics and 
pharamacokinetics, and intrinsic biocompatibility.5-9 Nanoparticles are unique as they take 
advantage of the enhanced permeability and retention (EPR) effect (Figure 1.1).1 This effect 
arises from the ability of small particles to permeate through the leaky vasculature of tumor 
tissue and be retained due to poor lymphatic drainage present in the tumor. The EPR effect is 
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considered a mode of passive targeting as nanoparticles are too large to enter the highly 
ordered vasculature of normal, healthy tissue. Thus, nanoparticles, if remaining in circulation 
long enough, eventually will accumulate in the tumor region. 
 
Figure 1.1. Illustration of the EPR effect in which nanoparticles are too large to penetrate the 
ordered vasculature of normal tissue but can permeate through the leaky vasculature of 
diseased tissue and are retained there due to poor lymphatic drainage. Courtesy of Demin 
Liu. 
 
Additionally, nanoparticles can be actively targeted to diseased tissues (e.g., tumor 
regions) by conjugation with targeting ligands and can be engineered to contain multiple 
agents (e.g., imaging and therapeutic agents for both imaging and therapy), both of which are 
much more difficult to achieve with conventional therapeutics. The clinical success of 
nanoparticle therapies such as Abraxane and Doxil illustrates the power of this approach. A 
large number of promising nanoparticle-drug conjugates are currently in different stages of 
clinical development.1,3,4 
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Metal-organic frameworks (MOFs) are a new class of highly tunable hybrid materials 
crafted from metal-connecting points and organic polydentate ligands.10 They are typically 
synthesized under mild conditions via coordination-directed self-assembly processes (Figure 
1.2), and are also called coordination polymers or coordination networks.11-15 Known for their 
large porosities with tunable pore sizes, shapes, and functionalities, MOFs are well studied 
among the scientific community for many applications such as nonlinear optics, gas storage, 
catalysis, chemical sensing, and separations.10,11,14-21 MOFs exhibit many desirable 
characteristics as drug carriers, including exceptionally high surface areas and large pore 
sizes for drug encapsulation, intrinsic biodegradability as a result of relatively labile metal-
ligand bonds, and versatile functionality for post-synthetic grafting of drug molecules.  
 
Figure 1.2. Formation of MOFs by coordination-directed self-assembly processes and the 
loading of drugs into MOFs via physical encapsulation.  Only one unit of an infinite MOF 
framework is shown for clarity. 
 
Recently, MOFs have been investigated for applications in loading and release of 
several drug molecules. When scaled down to the nano-regime to form nanoscale metal-
organic frameworks (NMOFs), or nanoscale coordination polymers (NCPs), these materials 
exhibit the same beneficial properties as their bulk counterparts but also possess interesting 
characteristics that are unique to nanomaterials. NCPs can be formed from a number of self-
assembly processes, each of which is illustrated in Figure 1.3.22-24 The most straightforward 
MOF 
Metal           Ligand       Drug Encapsulation 
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of these methods is a solvothermal synthesis in which the metal and ligand molecules are 
heated in a solvent, which can lead to amorphous or crystalline products. NCPs can also be 
synthesized in reverse (water-in-oil) microemulsions in which the reactants are suspended in 
surfactant-stabilized aqueous droplets in an organic phase. These droplets behave as 
nanoreactors, facilitating the assembly of the NCP material. This strategy can also be utilized 
in a surfactant-templated heating method in which a reverse microemulsion is heated to 
facilitate the reaction. Finally, NCPs can be formed via rapid precipitation, in which a 
solution of reactants is precipitated with a solvent, usually resulting in the formation of 
amorphous particles.  
 
Figure 1.3. Synthetic techniques for NCPs. (1) Reverse microemulsion, (2) Surfactant-
templated synthesis, (3) solvothermal synthesis, (4) rapid precipitation. 
 
NCPs are potential nanovectors for delivering therapeutic agents to targeted areas of 
the body, as drug release can be controlled with their large surface areas, high porosities, and 
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presence of functional groups to interact with loaded moieties. Our group has recently 
reported NCPs as important delivery vehicles for contrast enhancement agents for magnetic 
resonance imaging, computed tomography, and optical imaging;25-31 however, this chapter 
will focus on applications of MOFs and NCPs as potential drug delivery vehicles. Although 
their drug delivery applications are still in their infancy, NCPs exhibit many desired 
characteristics as nanocarriers. Intrinsic tunability and biodegradability, as well as 
exceptionally high drug loading capacity, of this emerging class of hybrid nanomaterials 
should make these systems promising candidates for further development as 
nanotherapeutics.    
1.2. Proof of Concept: Drug Release from MOFs 
In developing MOFs for drug delivery, the goal is to design carriers that possess 
minimal toxicity in the body; biocompatibility of both the metal and bridging ligand must be 
considered. While chromium and other metals are highly toxic, some metals exist in 
appreciable amounts in the body. For example, iron is a component of hemoglobin and has a 
concentration of approximately 22 µM in blood plasma. Tissues also contain various metals, 
such as copper (68 µM), manganese (180 µM), nickel (2 µM), and zinc (180 µM).32 Since 
this is an emerging class of drug carriers, there are very limited data on the biological fate of 
NCP platforms. Iron oxide nanoparticles are clinically approved as MRI contrast agents, and 
in vitro assays have shown that these particles are not cytotoxic.33 
The first group of MOFs to be investigated as a potential drug delivery system is the 
MIL (Materials of Institut Lavoisier) family, pioneered by Férey and co-workers.34 This 
investigation occurred as the Lin group first explored the applications of NCPs as potential 
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MRI contrast agents.26  The MIL family of MOFs is crafted from trivalent metal centers and 
carboxylic acid bridging ligands and holds great promise in drug delivery for their attractive 
characteristics: large pores (25-34 Å), outstanding surface areas (3100-5900 m2/g), and the 
ability to incorporate functional groups into the framework.   
Férey and co-workers studied the storage and release of Ibuprofen with chromium-
based MIL-101 (Figure 1.4) and MIL-100.35  Both materials showed high Ibuprofen loadings, 
with 0.347 g Ibuprofen/g MOF for MIL-100 and 1.376 g Ibuprofen/g MOF for MIL-101. The 
drastic difference in drug loading between the two materials is attributed to the pore sizes of 
the materials; MIL-101 has larger pore volumes of 12700 and 20600 Å (8200 and 12700 Å 
for MIL-100). The kinetics of Ibuprofen release was investigated by suspending the 
Ibuprofen-loaded materials in simulated body fluid (SBF) at 37 °C. There is an initial release 
of weakly-bound drug molecules within the first 2 h for MIL-100, and the entire cargo is 
released within 3 days. For MIL-101, steady release is observed for the first 8 h, with 
complete release after 6 days. These MOFs contain toxic chromium, and thus, the use of 
these materials for drug delivery is limited. A less toxic analog, MIL-101(Fe) has been 
developed as a biocompatible alternative.36 
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Figure 1.4. The structure of MIL-101. The tetrahedra are assembled from trivalent metal 
centers (Cr or Fe) and 1,4-benzenedicarboxylate. MIL-101 possesses larger pores than MIL-
100, which facilitates Ibuprofen loading. 
 
The Férey group has also reported controlled drug release for MIL-53, a more flexible 
MOF in the MIL family.37 Both MIL-53(Cr) and the less toxic MIL-53(Fe) achieved loadings 
of 0.220 g Ibuprofen/g MOF and 0.210 g Ibuprofen/g MOF, respectively. The delivery 
kinetics were investigated in SBF at 37 °C; complete drug delivery occurred in 3 weeks, a 
long release time attributed to the flexibility of the MIL-53 framework and strong drug-
framework interactions. This prolonged drug release gives MIL-53 the potential of being 
used for sustained release and drug delivery. The drug loadings achievable with the MIL 
family are much higher than any material previously studied for drug encapsulation (through 
non-covalent interactions).  Given the ability to construct highly porous MOFs with tunable 
hydrophobicity from practically any metal center, the possibilities are unlimited. 
 MOFs with hydrophobic pores such as the MIL family are ideal for encapsulating 
drug molecules that possess poor aqueous solubility.  MOFs can also be designed to have 
hydrophilic pores that can carry either positive or negative charges, and such MOFs can be 
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used to encapsulate drugs that contain opposing charges to the MOFs.  Rosi and co-workers 
recently developed an anionic MOF composed of Zn(II) ions, adenine, and para-
biphenyldicarboxylic acid that can be cationically-triggered to release its cargo.38 The MOF 
is anionic, so its use for storage and release of cationic drugs via exchange with cations in 
biological fluid was investigated. The MOF was loaded with 0.22g/g of hydrochloride salt of 
procainamide, an antiarrythmia drug. Procainamide therapy is currently limited by its rapid 
clearance from the body, requiring dosing every 3 to 4 h.  The drug release behavior of the 
MOF was monitored by HPLC; complete release was observed at 72 h in phosphate buffered 
saline (PBS). In contrast, the drug-loaded MOF was also dialyzed against pure water, with 
only 20% of the drug released, suggesting that the majority of procainamide is released by 
the cations present in PBS. In addition, the authors demonstrated that the framework 
remained intact under these conditions. 
 MOFs have also been studied as carriers for gaseous therapeutics which represent a 
significant challenge for drug delivery.  Nitric oxide (NO) has several applications in 
therapy, including antibacterial, antithrombotic, and wound-healing applications.39,40 The 
storage and release of nitric oxide (NO) in a MOF was investigated by Morris and co-
workers.41 Two MOFs were synthesized by a previously reported procedure,42 from either 
cobalt or nickel and 2,5-dihydroxyterephthalic acid. These MOFs can absorb 7 times the 
amount of NO than any previously reported material on a per gram basis via ligation to 
coordinatively unsaturated metal centers, with little background release.43 Figure 1.5 depicts 
the activation, loading, and release of NO by these MOFs.  
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Figure 1.5. Absorption, storage, and release of nitric oxide (NO) in a Co or Ni MOF. 
Activation occurs by dehydration of the MOF at 110 °C, followed by NO loading at room 
temperature. Finally, delivery (release) of NO is triggered when the MOF was exposed to 
11% relative humidity. (Pink spheres indicate water molecules, red and blue spheres indicate 
nitric oxide.)   
The effect of the NO-loaded MOFs on precontracted pig coronary arteries was 
investigated; the MOFs resulted in more vessel relaxation than the NO-free control. While Ni 
and Co are too toxic to be used for biological applications, the work discussed thus far shows 
the ability of MOF materials to absorb and release large amounts of therapeutic cargo.  The 
ability to deliver significant doses of NO is also relevant to cancer therapy since NO has 
shown anticancer activity in high concentrations, but shows tumorigenic properties at lower 
concentrations. The concentration at which this switch occurs is unknown.44,45 
1.3. Drug Delivery with Nano-MOFs  
While the systems discussed above illustrate the promise of MOFs as drug delivery 
vehicles, in vivo applications of the bulk MOFs are however limited because they are not 
suitable for systemic circulation due to their large sizes or toxicity.  The bulk MOFs thus 
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need to be scaled down to the nano-regime so that the resulting NCPs can circulate 
systemically while maintain the advantageous properties of bulk MOFs for drug delivery. 
NCPs can improve the pharmacokinetic properties of the encapsulated drugs.1,5,7 
Not only can small molecule agents be encapsulated within a MOF framework, the 
drug can also be incorporated within the framework directly as the bridging ligand. The Lin 
group was able to fabricate an NCP (designated as NCP-1) from Tb(III) ions and c,c,t- 
[PtCl2(NH3)2(O2CCH2CH2CO2H)2]  (disuccinatocisplatin, DSCP), a Pt(IV) cisplatin 
prodrug.46 The NCP-1 nanoparticles were 58.3 ± 11.3 nm in diameter by dynamic light 
scattering (DLS), and were encapsulated with silica to enhance stability (half-life, t1/2, of 9 h 
in HEPES buffer at 37°C, compared to 1 h for as-synthesized NCPs). Silica-coated NCP-1 
particles were further functionalized with c(RGDfk), a cyclic peptide that targets the ανβ3 
integrin, which is overexpressed in many epithelial cancers. The cytotoxicity of the 
nanoparticles was investigated against HT-29 human colon adenocarcinoma cells. These 
particles displayed a lower IC50 (Inhibitory Concentration, 50%) than that of free cisplatin 
(9.7 µM vs. 13.0 µM for cisplatin), while the untargeted particle did not exhibit significant 
cell death. The improved cytotoxicity of the c(RGDfk)-functionalized particles suggests that 
these particles are taken up by receptor-mediated endocytosis, followed by reduction to the 
active Pt(II) species by the reducing environment inside the cell (Figure 1.6).  The ability to 
transform from a relatively nontoxic prodrug to a highly potent anticancer drug in such a 
delivery scheme is quite attractive since it facilitates selective delivery of anticancer drugs to 
cancerous cells, which can in turn lower the dose-limiting side effects that plague most 
anticancer chemotherapeutics.   
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Additionally, small molecule anticancer agents can be incorporated into a MOF 
framework by post-synthetic grafting of a prodrug into the framework. The Lin group 
reported loading and release of biomedical agents in nanoMIL-101(Fe).47 This is the first 
report of the synthesis of an NCP and subsequent loading of a fluorophore and anticancer 
agent via post-synthetic modification (Figure 1.7). The NCP particles of MIL-101(Fe) were 
octahedral particles of about 200 nm in diameter with impressive porosity, a Langmuir 
surface area of 3700-4535 m2/g. Amino-functionalized nanoMIL-101 was synthesized by 
incorporating 2-aminoterephthalic acid in the synthesis. A Bodipy fluorophore was grafted 
on the NCP through a covalent amine bond with up to 11 wt% loading. Confocal microscopy 
of the Bodipy-loaded particles with HT-29 cells showed fluorescent signal only with those 
cells incubated with the particles, indicating that the particles are able to permeate the cell 
membrane and release their fluorescent cargoes. Additionally, a Pt(IV) prodrug, c,c,t- 
[PtCl2(NH3)2(OEt)(O2CCH2CH2CO2H] (ethoxysuccinatocisplatin, ESCP) was grafted on 
amino-functionalized nanoMIL-101, with an overall drug loading of 12.8 wt%.  
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Figure 1.6. A) Schematic showing the synthesis of Tb-DSCP NCP (NCP-1) and its 
subsequent coating with a silica shell (NCP-1´) and conjugation with a cyclic peptide. (PVP 
= polyvinylpyrollidone, TEOS = tetraethylorthosilicate)  B) TEM micrograph for as-
synthesized NCP-1.  C) TEM and D) SEM micrographs for NCP-1′.  E) In vitro cytotoxicity 
assay curves for HT-29 cells obtained by plotting the % cell viability against the Pt 
concentration of various samples and free cisplatin control. 
13 
 
 
Figure 1.7. NanoMIL-101 can be loaded both with an optical imaging agent and a cisplatin 
prodrug. Simultaneous release of the fluorophore and cisplatin prodrug allows real-time 
monitoring of drug delivery by optical imaging.   
 
The particles were coated with silica to enhance stability in vitro, giving a t1/2 of 14 h 
in PBS at 37 °C, compared to 1.2 h for the uncoated particles. Silica-coated particles were 
grafted with the cyclic peptide c(RGDfk) and studies with the functionalized particles against 
HT-29 cells showed that the particles had comparable cytotoxicity to that of free cisplatin 
(IC50 = 21 µM for the particles, IC50 = 20 µM for cisplatin, IC50 = 29 µM for silica-coated, 
untargeted particles). Grafting of both an optical imaging agent and a cisplatin prodrug into 
the nanoMIL-101 system suggests the potential of using such a platform for theranostic (both 
diagnosis and therapy with a single nanoparticle) applications that allow real-time monitoring 
of therapeutic responses of an anticancer drug.    
 It is worth noting that several related inorganic nanoparticle systems have also been 
developed as potential anticancer therapeutics. O’Halloran and co-workers were able to 
improve efficacy of the leukemia agent, As2O3, by formation of insoluble metal-arsenate 
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complexes inside liposomes.48,49 As2O3 is a potent therapy for leukemia, limited by its severe 
side effects and poor pharmacokinetics. Salts of nickel, cobalt, copper, and zinc were 
incorporated into liposomes, followed by loading of As(OH)3 to form insoluble M(II) 
complexes of As2O3. Folate-targeted liposomes with Ni/As2O3 showed high cytotoxicity 
against HeLa cervical cancer cells with an IC50 of 1.8 ± 0.6 µM (IC50 = 4.3 ± 0.3 µM for free 
As2O3). Recently, O’Halloran and co-workers were able to co-encapsulate As2O3 and a 
cisplatin-like drug (acetate salt of diaqua-cisplatin) inside a liposome using the same 
strategy.50 This formulation exhibited comparable cytotoxicity to As2O3 and diaqua-cisplatin 
alone, with several different cancer cell lines. Adair and coworkers were able to successfully 
encapsulate organic fluorophores and hydrophobic chemotherapeutics within calcium 
phosphate nanoparticles.51,52 Calcium phosphate nanoparticles provide a pH-tunable way to 
deliver encapsulated molecules to targeted cells with minimal background release. Ceramide, 
an apoptosis inducer, was encapsulated into the nanoparticles during synthesis. Preliminary 
in vitro cell assays against breast cancer and melanoma cell lines revealed that the 
nanoparticle conjugate showed highly effective induction of apoptosis, while the nanoparticle 
carrier displayed little toxicity. Additionally, the Ceramide-containing calcium phosphate 
conjugate showed activity in resistant cell lines. Although these systems are not NCPs, they 
share some of the same design principles as NCP-based nanotherapeutics. 
1.4. Conclusion 
Significant progress has been made in adapting MOFs and NCPs for drug delivery. 
With these hybrid systems, a multitude of metal centers and organic building blocks can be 
pieced together and specifically tailored to form new materials with desirable characteristics 
as drug delivery vehicles. Since NCPs represent an infinitely tunable material platform, many 
15 
 
other drugs can be incorporated into them in a foreseeable future.  The ability to carry both 
imaging and therapeutic agents in NCPs should greatly facilitate the efficacy studies of this 
promising class of nanotherapeutics.  The future for MOFs and NCPs in drug delivery is 
bright, although many more improvements are needed before these materials can be 
considered for clinical applications. 
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CHAPTER 2 
 
Lipid-Coated Nanoscale Coordination Polymers for Targeted Delivery of Methotrexate 
 
(Portions of this chapter were adapted with permission from Huxford, R.C.;† deKrafft, K.E.;† 
Boyle, W.S.; Liu, D.; Lin, W. Chem. Sci. 2012, 3, 198. †Contributed equally to this work. 
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2.1. Introduction 
2.1.1. Conventional Cancer Chemotherapy - Methotrexate 
  Conventional cancer chemotherapy regimens consist of a single small molecule agent 
or a combination of agents. Despite the high efficacy of these therapies, current treatments 
are limited by nonspecific distribution throughout the body leading to high doses, rapid 
clearance, narrow therapeutic windows, poor pharmacokinetics, and high side effects.1 One 
such chemotherapeutic agent is methotrexate (MTX), shown in Figure 2.1.  
 
Figure 2.1. Structure of the antifolate methotrexate (MTX).  
 
  MTX belongs to a group of anticancer agents known as antifolates, small molecules 
20 
 
that are structurally similar to folic acid and can thus mimic this essential nutrient, causing 
havoc throughout the folic acid pathway. MTX works by inhibiting dehydrofolate reductase, 
thus preventing DNA synthesis and inducing apoptotic cell death. While MTX is quite 
efficacious and is the first-line treatment for acute lymphoblastic leukemia (ALL), this 
efficacy is compromised by the array of drawbacks associated with conventional small 
molecule chemotherapeutics.2 Large doses of MTX are required as a result of its nonspecific 
distribution and rapid renal clearance, which often leads to systemic toxicity. Prolonged 
MTX treatment results in numerous side effects such as mucositis, hematological toxicity, 
and secondary cancer. In the attempt to alleviate the therapeutic drawbacks, a few MTX-
containing nanoparticle systems (polymer conjugates and liposomes) have been developed; 
however, these vehicles contain relatively low drug loadings.3-8 Thus, we hypothesized 
incorporation of MTX directly into an NCP framework by coordination of the two 
carboxylate groups of MTX to metal centers. This chapter highlights the use of NCPs to 
deliver the antifolate chemotherapeutic, MTX; very high loadings of MTX can be achieved 
in such formulations (up to 79.1 wt%). This chapter includes the synthesis and 
characterization of MTX-based NCPs, their stabilization and cancer targeting with a lipid 
bilayer, and in vitro efficacy against Jurkat ALL cells (Figure 2.2). A carboxylic acid 
derivative of the phosphor Ru(bpy)32+ (bpy = 2,2’-bipyridine) was also incorporated into the 
NCPs to allow the monitoring of MTX uptake by cancer cells via confocal microscopy. 
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Figure 2.2. Schematic showing the solvothermal synthesis of MTX- and folate-containing 
NCPs, encapsulation with a lipid bilayer containing a targeting ligand, and cell uptake and 
release. 
 
 2.1.2. Previous Methotrexate-Based Nanoscale Coordination Polymers 
 Two generations of MTX-containing NCPs were reported previously and serve as the 
foundation for this work.9 The first MTX-containing NCP, based on Zn(III) (Zn-MTX, 
Figure 2.3a and 2.3c), possessed a very high MTX loading by thermogravimetric analysis 
(TGA, 79.1 wt%, Figure 2.4), but were unstable in aqueous conditions due to the labile 
nature of the Zn-carboxylate bond. We hypothesized that Zr(IV) would build a more stable 
MTX-containing NCP due to the reported stability of the Zr-carboxylate bond in MOF 
frameworks.10 Nanoparticles of Zr-MTX (78.2 wt% MTX by TGA, Figures 2.3b, 2.3d, and 
2.5) were synthesized but could not be further stabilized (t1/2 in PBS ~ 30 min) by coating 
with a biocompatible layer (silica or lipid coating). This instability can be explained by the 
high driving force of Zr(IV) to form phosphate salts (Zr3(PO4)4,  ksp = 10-134). The following 
work utilizes Gd(III) as the binding metal (GdPO4, ksp = 10-23), stabilizes the resulting NCPs 
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by encapsulation in a lipid bilayer (liposome), and exhibits cytotoxicity and enhanced uptake 
in Jurkat ALL cells. 
 
  
  
Figure 2.3. SEM micrographs of (a) Zn-MTX and (b) Zr-MTX. TEM micrographs of (c) Zn-
MTX and (d) Zr-MTX.  
 
a) b) 
c) d) 
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Figure 2.4. TGA plot of Zn-MTX, showing organic weight loss between 250 and 500 °C 
attributed to MTX (79.1 wt%). 
 
 
 
Figure 2.5. TGA plot of Zr-MTX, showing organic weight loss between 250 and 500 °C 
attributed to MTX (78.2 wt%). 
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 2.1.3. Liposomes 
Liposomes, bilayers of typically phospholipids, are known to stabilize 
nanomaterials.11-14 The coating process presumably occurs via charge-charge interactions 
between oppositely-charged particles and liposomes.15 Liposomes are formed by the self-
assembly of lipids dispersed in aqueous solution, which forms liposomes that are 
multilamellar (containing concentric layers). The liposome diameter can be refined by 
development of multilamellar liposomes through an extruder to yield monodisperse 
liposomes containing one bilayer (unilamellar).16 These liposomes can be mixed with an 
aqueous particle dispersion, and the liposomes rearrange to result in encapsulation of 
individual particles (Figure 2.6). The addition of a lipid bilayer to a particle surface can result 
in enhanced stability as liposomes are mostly impermeable to moieties such as salts and 
macromolecules, compounds known to rapidly degrade particles under biological 
conditions.12,17,18 
 
Figure 2.6. Illustration showing self-assembled liposome formation via hydration of a lipid 
film, followed by encapsulation of individual particles within lipid bilayers. Reproduced with 
permission from reference 15. 
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2.2. Results and Discussion 
2.2.1. Lipid Coating of Zr-MTX NCP 
Briefly, liposomes containing cationic lipids DOTAP (1,2-dioleoyl-3-
trimethylammonium propane) or DSTAP/DOPE (DSTAP = 1,2-stearoyl-3-
trimethylammonium propane, DOPE = L-α-phosphatidylethanolamine, dioleoyl) were 
prepared by reduction of lipids in chloroform to a lipid film, hydration in 1 mM aq. KCl, and 
extrusion through a series of polycarbonate filter membranes. For example, DOTAP 
liposomes with a Z average diameter of 51.9 nm, PDI of 0.105, and ζ potential of 68.3 mV 
were produced by this method (Figure 2.7). 
 
Figure 2.7. TEM micrograph of DOTAP liposomes using Pt(II) as a stain. 
 
 Several attempts were made to stabilize Zr-MTX by encapsulation within a lipid 
bilayer. Several formulations of liposomes were prepared (all molar ratios): 1:1 
DOTAP/cholesterol, 5:62:33 DOTAP/DOPE/cholesterol, 100% DOTAP or DSTAP, and 1:1 
DSTAP/DOPE. Lipid coatings using all of these formulations were evidenced by DLS size 
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and ζ potential plots, but encapsulation with a lipid bilayer did not result in stabilization of 
the Zr-MTX NCP. The following will illustrate an example: encapsulation of Zr-MTX with 
1:1 (by mol) DOTAP/cholesterol liposomes. A dispersion of Zr-MTX in 1 mM aq. KCl was 
mixed with different amounts of 1:1 (by mol) DOTAP/cholesterol liposomes, resulting in 
different particle:liposome weight ratios. Monitoring the Z average diameter and ζ potential 
of the samples by DLS (Figure 2.8) can indicate successful lipid encapsulation. As liposomes 
are added to the NCP dispersion, aggregation is observed when some liposomes are added, 
followed by stabilization in Z average as the addition of more liposomes alleviates the 
aggregation. Encapsulation can also be monitored via changes in ζ potential; the potential 
increases from a negative value (non-coated particles = -26.2 mV) to a positive value that 
approaches that of the liposome dispersion (72.6 mV). 
 
Figure 2.8. DLS plots of ζ potential and Z average of Zr-MTX NCPs given increasing 
amounts of 1:1 (by mol) DOTAP/cholesterol liposomes. As more liposomes are added to the 
formulation, ζ potential stabilizes at a positive value and aggregation dissipates.  
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By SEM, the lipid-coated Zr-MTX particles, Zr-MTX@Lipid, do not differ from the 
as-synthesized particles, but use of a uranyl acetate stain with TEM imaging shows evidence 
of the DOTAP/cholesterol lipid bilayer (Figure 2.9). Uranyl acetate produces a dark ring 
around as-synthesized Zr-MTX since uranyl ions bind preferentially to carboxylates on the 
NCP surface.15 In lipid-coated particles, this dark ring is not present since the particles are 
lipid-coated and the uranyl acetate cannot permeate the lipid bilayer to bind with the particle. 
Despite the accumulating evidence of lipid encapsulation of Zr-MTX with 
DOTAP/cholesterol liposomes, the formulation did not stabilize the NCP, as shown by a 
release profile of Zr-MTX@Lipid in 8 mM PBS at 37 °C (Figure 2.10). 
  
Figure 2.9. TEM micrographs of (a) Zr-MTX and (b) Zr-MTX@Lipid treated with uranyl 
acetate stain. Zr-MTX has a dark surface due to binding of uranyl acetate to surface 
carboxylates, a phenomenon not observed for Zr-MTX@Lipid due to shielding of the NCP 
surface by the lipid bilayer. 
 
a) b) 
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Figure 2.10. Release profile of Zr-MTX and Zr-MTX@Lipid in 8 mM PBS at 37 °C 
showing no enhanced stabilization for the lipid-coated formulation (t1/2 ~ 30 min). 
 
 
After several attempts to stabilize Zr-MTX via lipid encapsulation, we speculated that 
Zr-MTX could not be stabilized due to the great driving force of Zr(IV) to form Zr3(PO4)4 
(ksp = 10-134). Since phosphates of trivalent lanthanides have lower ksp values, we sought to 
fabricate MTX-containing NCPs using lanthanide (III) metals. 
2.2.2. Synthesis and Characterization of La-MTX and Pr-MTX NCPs 
NCPs of La-MTX were synthesized by a solvothermal method in which MTX and 
LaCl3·7H2O were heated in DMF at 80 °C. The resulting spherical particles were 300-500 
nm in diameter by SEM (Figure 2.11). The large size of these particles precluded their use in 
biological applications. Several attempts were made to reduce the diameter of this 
formulation, but all were unsuccessful. 
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Figure 2.11. SEM micrograph of La-MTX NCPs. 
 
 NCPs using the trivalent lanthanide praseodymium were produced by a similar 
solvothermal method to La-MTX. These particles are spherical and between 150-300 nm in 
diameter by SEM (Figure 2.12), with a Z average diameter of 235.6 nm, PDI of 0.192, and ζ 
potential of -15.3 mV by DLS. Pr-MTX has an exceptionally high MTX drug loading of 63.7 
wt% by TGA (Figure 2.13). These particles are too large for biomedical applications, and the 
effect of Pr in biological systems is unknown, so these particles were not explored further. 
 
Figure 2.12. SEM micrograph of Pr-MTX NCPs. 
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Figure 2.13. TGA of Pr-MTX, showing organic weight loss between 250 and 550 °C 
attributed to MTX. 
 
 
2.2.3. Synthesis and Characterization of Gd-MTX NCP 
Nanoparticles of Gd-MTX were produced by a solvothermal technique in which 
equal molar amounts of Gd(NO3)3·6H2O and MTX were heated in DMF at 80 °C for 5 min. 
This reaction afforded a yellow product in ~85% yield. These NCPs are between 70-200 nm 
by both SEM and TEM with a diameter (number average) of 77.7 nm (Figure 2.14) and PDI 
of 0.040 by DLS, indicating a highly monodisperse sample. Gd-MTX possesses a high MTX 
drug loading of 71.6 wt% by TGA (Figure 2.15). Particles of Gd-MTX have a ζ potential of -
10.0 mV, indicating that these particles can be encapsulated with a cationic lipid bilayer. 
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Figure 2.14. SEM (a) and TEM (b) micrographs of Gd-MTX NCPs. 
 
Figure 2.15. TGA of Gd-MTX showing organic weight loss between 250 and 500 °C 
attributed to MTX. 
 
 
2.2.4. Lipid Coating of Gd-MTX NCP 
As-synthesized Gd-MTX NCPs were encapsulated in a 1:1 (by mol) DSTAP/DOPE 
lipid bilayer by mixing dispersions of liposomes and particles in 1 mM aq. KCl to yield Gd-
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MTX@Lipid. Successful lipid encapsulation was evidenced by monitoring the Z average 
diameter and ζ potential of the particle/liposome mixture with increasing liposome:particle 
weight ratios (Figure 2.16). Aggregation of the particles ceases and the ζ potential becomes 
positive with increased additions of liposomes, indicating successful lipid encapsulation. 
When Gd-MTX@Lipid is stained with uranyl acetate and imaged by TEM, a dark ring is 
evident presumably due to uranyl ions binding to the phosphates of the DOPE lipid,15 a 
phenomenon that is not observed for Gd-MTX (Figure 2.17). 
 
 
Figure 2.16. DLS plots of ζ potential and Z average of Gd-MTX NCPs with the addition of 
increasing amounts of 1:1 (by mol) DSTAP/DOPE liposomes. This plot shows that with 
increasing liposome amounts, the ζ potential becomes positive and the Z average diameter 
approaches that of free liposomes. 
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Figure 2.17. TEM micrographs of (a) Gd-MTX and (b) Gd-MTX@Lipid in the presence of 
uranyl acetate stain. Uranyl acetate forms dark rings on the surface of the lipid-coated 
formulation due to binding to the phosphates of the DOPE lipid. 
 
Only a slight decrease in particle size from the as-synthesized particles is observed by 
DLS; particles of Gd-MTX@Lipid were 64.6 nm (number average) with a PDI of 0.240. The 
decrease in size can be attributed to a decrease in aggregation due to the lipid coating. The 
lipid-coated particles have a cationic ζ potential (32.6 mV) due to presence of the lipid 
bilayer on the particle surface. Further evidence of lipid encapsulation can be observed by 
laser scanning confocal microscopy. Gd-MTX particles doped with the optical imaging agent 
Ru(bpy)32+ (discussed in section 2.2.7) were encapsulated with a 1:1 (by mol) DSTAP/DOPE 
bilayer containing 10 mol% DOPE-FITC, another optical imaging agent. When the particles 
are imaged by confocal microscopy, co-localization of the red channel (particles) with the 
green channel (FITC) indicates individual particles are associated with lipid bilayers (Figure 
2.18). Encapsulation of Gd-MTX with a DSTAP/DOPE lipid bilayer results in significant 
stabilization of the material in a release profile in 8 mM PBS at 37 °C (Figure 2.19). The as-
synthesized particles are quite unstable, with t1/2 ~ 2 h, but the lipid-coated formulation has a 
t1/2 ~ 23 h, with complete release at 192 h. The amount of MTX released was determined by 
UV-Vis spectroscopy. MTX absorbs in the 200-400 nm region (Figure 2.20), and a standard 
a) b) 
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curve was determined using the absorbance at ~305 nm (Absorbance305 nm = 0.0222(µM 
MTX). 
 
Figure 2.18. Confocal microscopy images of Ru(bpy)3-doped Gd-MTX@Lipid in which the 
lipid bilayer has been doped with 10 mol% DOPE-FITC. This experiment was conducted to 
show co-localization of NCP fluorescence with the fluorescence of the lipid bilayer. a) DIC 
image, b) red fluorescence due to NCPs, c) green fluorescence due to FITC-doped lipid 
bilayer, and d) overlay of NCP and lipid bilayer fluorescences showing co-localization.  
 
Figure 2.19. Release profile for Gd-MTX@Lipid in 8 mM PBS at 37°C and using 10K 
mwco dialysis tubing. t1/2: free MTX = 1.5 h, Gd-MTX = 2 h, Gd-MTX@Lipid = 23 h. 
Complete MTX release from Gd-MTX@Lipid was observed at 143 h.   
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Figure 2.20. An absorption spectrum for MTX (black), compared to an absorption spectrum 
for a release profile aliquot from dialysis of Zn-MTX (red).  The absorption profile does not 
change significantly, indicating that MTX remains unchanged under the synthetic conditions 
used.   
 
The Gd-MTX@Lipid NCPs were rendered an active tumor targeting agent by doping 
the 1:1 (by mol) DSTAP/DOPE liposomes with 10 mol% of an anisamide (AA)-lipid 
conjugate, DOPE-AA. Anisamide is a small molecule targeting ligand that is known to target 
sigma receptors which are overexpressed on a number of epithelial cancer cell lines.19-24 
Addition of AA to the liposome formulation did not significantly alter the size of the 
particles, as Gd-MTX@Lipid-AA has a number average diameter of 76.8 nm, PDI of 0.150, 
and a ζ potential of 25.3 mV. 
2.2.5. Synthesis and Characterization of Gd-Folate NCP 
Control vehicles, NCPs that do not contain any cytotoxic agent, were prepared using 
folic acid, an essential nutrient, instead of MTX. These particles were prepared by a 
solvothermal method in which GdNO3·6H2O and folic acid were heated in DMF at 80 °C, 
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producing particles that were between 200-300 nm by SEM with a number average diameter 
of 262 nm by DLS (Figure 2.21). These control vehicles were used to show that in vitro 
cytotoxicity arises from MTX, not Gd(III) or the lipid formulation.  
 
Figure 2.21. SEM micrograph of Gd-Folate NCPs. 
 
2.2.6. In Vitro Cytotoxicity and Viability Assays 
A minimal amount of in vitro cytotoxicity assays were performed on Zr-MTX using 
the acute lymphoblastic leukemia cell line, CCRF-CEM. A 3 h cytotoxicity assay was 
performed in which concentrations of free MTX, Zr-MTX, and Zr-MTX@SiO2 were tested. 
Viability was determined by the trypan blue exclusion assay (Figure 2.22). The results show 
that free MTX and Zr-MTX exhibit similar IC50 values, 20 µM and 18 µM, respectively. The 
similarity in efficacy can be explained by the instability of Zr-MTX; Zr-MTX would dissolve 
rapidly and essentially become free MTX in the cell medium. Additionally, the efficacies of 
free MTX and Zr-MTX were equivalent when tested over 48 h, with an IC50 value of ~1 µM 
(Figure 2.23). 
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Figure 2.22. In vitro viability curves of MTX and Zr-MTX against the CCRF-CEM acute 
lymphoblastic leukemia cell line over 3 h. 
 
 
Figure 2.23. In vitro viability curves of MTX and Zr-MTX against the CCRF-CEM acute 
lymphoblastic leukemia cell line for 48 h. 
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 All Gd-MTX formulations were tested against Jurkat cells, an ALL cell line that is 
known to overexpress sigma receptors.23 This assay was completed over 72 h, and 
cytotoxicity was determined by the trypan blue exclusion assay (Figures 2.24 and 2.25). As-
synthesized Gd-MTX was slightly less cytotoxic than free MTX (IC50 = 34.7 ± 2.5 nM) with 
an IC50 value of 54.7 ± 2.3 nM. The efficacy of Gd-MTX is not expected to be an 
improvement over the free drug due to rapid degradation of these unstable NCPs. The lipid-
coated formulation showed enhanced efficacy over free MTX with an IC50 = 28.3 ± 0.6 nM, 
but the AA-modified particles showed an even more, statistically significant, increase in 
efficacy (IC50 = 23.7 ± 1.5 nM).  The enhancement in efficacy of the lipid-coated particles is 
attributed to the known affinity of cationic lipid bilayers for cell membranes.  
 
Figure 2.24. In vitro cytotoxicity curves for MTX-containing NCPs against Jurkat acute 
lymphoblastic leukemia cells.  
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Figure 2.25. IC50 plot of MTX-containing NCPs for a 72 h in vitro cytotoxicity assay against 
Jurkat ALL cells. 
 
 
 Viability assays testing the effect of Gd-Folate NCPs or free Gd(III) salt was 
conducted to ensure that the cytotoxicity of Gd-MTX can be attributed to MTX, not the 
Gd(III) ions or lipid bilayers. Free Gd(NO3)3 salt as well as Gd-Folate and the lipid-coated 
formulations of Gd-Folate were tested, and no cytotoxic effect was observed (Figure 2.26). 
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Figure 2.26. In vitro viability assay testing free Gd(III) and Gd-Folate NCPs, displaying that 
no cytotoxic effect was observed due to free Gd(III) or the control vehicles. This experiment 
confirms that the cytotoxicity observed for MTX-containing NCPs is due solely to MTX and 
no other agent. 
 
2.2.7. Synthesis and Characterization of Ru(bpy)32+-Doped Gd-MTX NCP 
 Gd-MTX doped with 2.5, 5, or 10 mol% Ru(bpy)32+ were prepared by a similar 
solvothermal method in which the undoped nanoparticles were prepared. Our previous work 
has shown that Ru(bpy)23+ is an efficient optical imaging agent,25 and these doped NCPs 
were prepared for confocal microscopy studies. All doped NCPs were between 100-200 nm 
in diameter by SEM and TEM (Figure 2.27). No additional weight loss is observed by TGA, 
presumably because the addition of Ru(bpy)23+ was too low to be detected (Figure 2.28). Gd-
MTX doped with 10 mol% Ru(bpy)23+ was used for confocal microscopy. These particles 
0
20
40
60
80
100
0 0.5 1 2.5 5 10
V
ia
bi
lit
y 
%
[Folate] (µM)
Gd-MTX
_@Lipid
_@Lipid-AA
Gd(III)
ipid
Gd-Folate
Lipid- A
Gd(III)
41 
 
have a number average diameter of 119.5 nm with a PDI of 0.154 and a ζ potential of -20.6 
mV. These particles are 9.6 mol% Ru by ICP-MS, and the presence of Ru(bpy)23+ is evident 
by fluorescence in which a broad emission peak at ~620 nm is present (Figure 2.29).  
  
 
Figure 2.27. SEM micrographs of Ru(bpy)32+-doped Gd-MTX with different doping 
amounts: (a) 2.5 mol%, (b) 5 mol%, (c) 10 mol%.  
 
a) b) 
c) 
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Figure 2.28. TGA plot of Gd-MTX doped with 5 mol% Ru(bpy)32+ showing organic weight 
loss attributed to bpy ligands and MTX. 
 
 
Figure 2.29. Fluorescence spectrum of Ru(bpy)32+-doped Gd-MTX showing emission from 
the presence of Ru(bpy)32+ (~620 nm). 
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 Ru(bpy)32+-doped Gd-Folate NCPs were also prepared by a solvothermal synthesis in 
DMF at 80 °C. These particles fluoresce under a UV lamp and are 150-200 nm by SEM 
(Figure 2.30). This size is also observed by DLS with a number average diameter of 160.6 
nm, PDI of 0.365, and ζ potential of -16.1 mV in 1 mM aq. KCl. These particles are 13.4 
mol% Ru by ICP-MS. 
 
Figure 2.30. SEM micrograph of Ru(bpy)32+-doped Gd-Folate NCPs. 
 
2.2.8. Confocal Microscopy 
Ru(bpy)32+-doped Gd-MTX NCPs were used to show that this system can be used as 
a dual optical imaging and chemotherapeutic agent. Amounts of Gd-MTX and lipid-coated 
formulations were incubated with Jurkat ALL cells for 1 h, followed by incubation with an 
AnnexinV-FITC conjugate, which is a fluorescent indicator for early apoptosis. These 
samples were visualized using a confocal microscope (Figure 2.31). No red (particles) or 
green (apoptosis) fluorescence is observed for the as-synthesized Gd-MTX NCPs, likely due 
to rapid degradation of these particles. The as-synthesized particles do not have a mechanism 
for cell internalization. Co-localized fluorescence of the Ru(bpy)32+-doped Gd-MTX particles 
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and green (FITC) fluorescence is observed for lipid-coated Gd-MTX, but this signal is 
greatly enhanced in the AA-targeted particles, indicating increased uptake and efficacy of 
this formulation.  
 
Figure 2.31. (a-c) Differential interference contrast (DIC) images and (d-i) fluorescence 
images of Jurkat cells incubated with Gd-MTX (d,g), Gd-MTX@DSTAP/DOPE (e,h), and 
Gd-MTX@DSTAP/DOPE-AA (f,i). Red fluorescence (d-f) is from the Ru(bpy)32+-doped 
particles and green fluorescence (g-i) is from the Annexin V FITC conjugate early apoptosis 
stain. Scale bars represent 25 µm. 
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 When Jurkat cells are incubated with Ru(bpy)32+-doped Gd-Folate NCPs and stained 
with the AnnexinV-FITC conjugate, red fluorescence is observed, but no green fluorescence 
from the early apoptosis indicator is observed (Figure 2.32). This control experiment 
emphasizes that cytotoxicity of this formulation is due to MTX, not Gd3+ or the lipid coating. 
        
Figure 2.32. Confocal images of Jurkat cells incubated with Gd-Folate (a-c), Gd-
Folate@DSTAP/DOPE (d-f), and Gd-Folate@DSTAP/DOPE-AA (g-i). Cells incubated with 
the AA-targeted formulation shows enhanced uptake, but no apoptosis is apparent. Channels 
are: a,d,g) DIC, b,e,h) red from particles, c,f,i) green from AnnexinV FITC apoptotic stain. 
Scale bars are 25 µm.   
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 2.2.9. MR Relaxivities of Gd-MTX NCPs 
 Gd-MTX and the lipid-coated formulations were probed as potential theranostic 
agents by taking advantage of the use of Gd(III) as a MRI contrast enhancement agent. 
Samples of the NCPs were prepared and redispersed in H2O then analyzed on a 3T MR 
scanner. MR relaxivities (r1 and r2) were analyzed (Figures 2.33, 2.34, 2.35, and 2.36). These 
values are acceptable for MR contrast agents, as many agents display r1 values between 4-5 
mM-1s-1. T1- and T2-weighted images of these formulations show increased contrast with 
increased concentration of NCPs suspended in H2O. It is likely that the as-synthesized Gd-
MTX nanoparticles display higher relaxivities because H2O exchange is impeded by the lipid 
coatings. 
 
Figure 2.33. MR relaxivity plots for Gd-MTX showing values for r1 and r2. 
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Figure 2.34. MR relaxivity plots for Gd-MTX@Lipid showing values for r1 and r2. 
 
Figure 2.35. MR relaxivity plots for Gd-MTX@Lipid-AA showing values for r1 and r2. 
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Figure 2.36. T2- (a) and T1- (b) weighted images for Gd-MTX, Gd-MTX@DSTAP/DOPE, 
and Gd-MTX@DSTAP/DOPE-AA. Varying concentrations increase from left to right. 
 
2.2.10. PEGylation of Gd-MTX NCP 
 Attempts were made to PEGylate the lipid bilayers of the Gd-MTX formulations as 
PEGylation is known to enhance circulation of nanomaterials in biological systems.26-30 Two 
methods were done: post-insertion (in which PEG-lipid is added after lipid coating) and pre-
insertion (in which PEG-lipid is added during lipid coating).31 Post-insertion was attempted 
a) 
b) 
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by lipid-coating Gd-MTX by the established procedure and then adding amounts of PEG-
DOPE micelles to result in varying mol% PEG-DOPE in the bilayer. Monitoring the ζ 
potential of the various samples in 1 mM aq. KCl can indicate if PEGylation was successful. 
Lipid-coated Gd-MTX has a cationic ζ potential (30.5 mV), and the ζ potential becomes 
more neutral with increased amounts of PEG-DOPE (Figure 2.37). This shift toward neutral ζ 
potentials is likely due to shielding by the bulky PEG-DOPE lipid. SEM shows that the 
particle size and morphology does not differ from the as-synthesized particles (Figure 2.38). 
Additionally, the number average diameters by DLS of the PEGylated particles are larger 
than the lipid-coated particles, likely due to increased bulk by addition of PEG (Figure 2.39). 
 
Figure 2.37. ζ potential plot of PEGylated Gd-MTX@Lipid that shows the decrease in ζ 
potential with increasing amounts of DOPE-PEG added to the formulation. 
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Figure 2.38. SEM micrograph of Gd-MTX PEGylated with DOPE-PEG by post-insertion. 
 
 
 
Figure 2.39. DLS plot showing the increase of number average diameter with increased 
additions of DOPE-PEG. 
 
 
PEGylated nanoparticles are often characterized by their PEG surface coverage. 
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nm2/PEG can be theoretically calculated (section 2.4.4.). The optimum PEG surface coverage 
was found for lipid-coated Gd-MTX with 15 mol% PEG added (Table 2.1), a PEG surface 
coverage of 2.3 nm2/PEG. 
 
Table 2.1. DOPE-PEG coverages of Gd-MTX NCPs PEGylated by post-insertion. 
DOPE-PEG   
(mol%) 
DOPE-PEG    
(wt%) 
DOPE-PEG 
(molecules/particle) 
PEG Coverage 
(nm2/PEG) 
5 2.3 6054 8.1 
10 4.5 9871 5.0 
15 8.2 18032 2.7 
 
The post-insertion method for PEGylating lipid-coated Gd-MTX NCPs was 
abandoned because there were concerns as to whether this approach compromised the 
stability of the lipid-coated formulation. It is known that increased amounts of PEG in a 
formulation can lead in instability because of the surfactant-nature of PEG lipids.32 Control 
experiments monitoring the change in number average diameter of PEGylated particles after 
subsequent washes and centrifugations showed that even after three washes, liposomes were 
prevalent in the supernatant, as indicated by a cationic ζ potential, indicating instability of the 
formulation. The pre-insertion method of liposomal PEGylation was also probed. This 
procedure is done by preparing PEG-containing liposomes followed by lipid encapsulation of 
the NCPs. Liposomes containing different amounts of PEG were prepared and analyzed for 
PEG content. Particles do not differ from the as-synthesized Gd-MTX by SEM (Figure 2.40), 
but an increase in number average diameter is observed by DLS, presumably due to addition 
of the bulky PEG lipid (Figure 2.41). PEG lipids and other organic molecules are not 
typically visible by SEM.  
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Figure 2.40. SEM micrograph of Gd-MTX@Lipid PEGylated with 5 mol% DOPE-PEG.  
 
 
 
Figure 2.41. DLS number average plots of Gd-MTX, Gd-MTX@Lipid, and PEGylated (5 
mol%) Gd-MTX@Lipid. 
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(3.0 nm2/PEG) is obtained using 10 mol% PEG-containing liposomes. PEG content 
decreases with 15 mol% PEG (4.9 nm2/PEG) likely due to destabilization of the lipid bilayer 
by the addition of excess PEG-DOPE. TGA comparing Gd-MTX, lipid-coated Gd-MTX, and 
PEGylated Gd-MTX shows that both lipid-coated formulations exhibit less organic weight 
loss (Figure 2.42). This observation disputes our hypothesis that lipid-coated formulations 
should possess more organic weight. Our conclusion is that lipid coating of this system, as 
well as with pre-inserted PEG liposomes, results in loss of some MTX drug loading. 
 
Table 2.2. DOPE-PEG coverages of Gd-MTX NCPs PEGylated by pre-insertion. 
DOPE-PEG   
(mol%) 
DOPE-PEG    
(wt%) 
DOPE-PEG 
(molecules/particle) 
PEG Coverage 
(nm2/PEG) 
5 5.0 10908 4.5 
10 7.5 6544 3.0 
15 4.6 10017 4.9 
 
 
Figure 2.42. TGA plots of Gd-MTX, Gd-MTX@Lipid, and PEGylated Gd-MTX@Lipid 
with 5 mol% DOPE-PEG by pre-insertion. 
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2.3. Conclusion 
 After unsuccessful stabilization of previously-synthesized Zr-MTX NCPs, Gd-MTX 
NCPs with an extremely high MTX drug loading (71.6 wt%) were synthesized by a 
solvothermal method and stabilized by encapsulation with a 1:1 (by mol) DSTAP/DOPE 
lipid bilayer. The formulation was rendered an active targeting agent by addition of an 
anisamide-DOPE conjugate which targets sigma receptors. Encapsulation of the NCP in a 
functionalized lipid bilayer allows for targeted delivery and controlled release to cancer cells, 
as shown by enhanced efficacy of the targeted formulation against Jurkat acute lymphoblastic 
leukemia cells. The NCPs were doped with the phosphor Ru(bpy)32+, and the resulting 
formulation was utilized as an optical imaging agent. Confocal microscopy exhibited 
enhanced uptake of the targeted NCPs. The lipid-coated Gd-MTX NCPs can be PEGylated 
using either a post- or pre-insertion method, but there is the possibility that addition of PEG 
to the lipid membrane using this procedure compromises the stability imparted by the 
membrane. 
2.4. Experimental Details 
2.4.1. Materials and Methods 
 
 All chemicals, unless otherwise noted, were purchased from Fisher or Sigma Aldrich 
and used without further purification. Methotrexate was purchased from TCI America. 1,2-
dioleoyl-3-trimethylammonium propane, chloride salt (DOTAP) and 1,2-stearoyl-3-
trimethylammonium propane, chloride salt (DSTAP) were purchased from Avanti Polar 
Lipids. L-α-phosphatidylethanolamine, dioleoyl (DOPE) was a gift from Sigma Aldrich. Cell 
culture supplies: fetal bovine serum (Sigma), RPMI-1640 growth medium (Gibco), 
penicillin-streptomycin (Sigma), and phosphate buffered saline (Gibco) were purchased from 
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the Tissue Culture Facility in the Lineberger Cancer Center at UNC-Chapel Hill. AnnexinV 
FITC conjugate was purchased from Invitrogen. 
Microwave reactions were carried out in a CEM Discovery microwave or a CEM 
MARS 5 microwave. Scanning electron microscopy (SEM) was performed with a Hitachi 
4700 Field Emission Scanning Electron Microscope, and transmission electron microscopy 
(TEM) was performed with a JEM 100CX-II Transmission Electron Microscope. A 
Cressington 108 Auto Sputter Coater equipped with a Au/Pd (80/20) target and MTM-10 
thickness monitor was used to coat samples before SEM imaging. SEM micrographs were 
obtained on glass slides, and TEM micrographs were obtained on carbon-coated copper 
grids.  Thermogravimetric analysis (TGA) was done on a Shimadzu TGA-50 equipped with a 
platinum pan, and samples were heated at a rate of 3°C/min under air. Powder x-ray 
diffraction (PXRD) data was gathered on a Bruker SMART APEX II diffractometer using Cu 
radiation, and powder patterns were analyzed with the APEX II package using the phase ID 
plugin. UV-Vis absorption spectra were obtained using a Shimadzu UV-2401 PC UV-Vis 
recording spectrophotometer. Size and zeta potential information was obtained on a Malvern 
ZetaSizer dynamic light scattering instrument. A Varian 820-MS Inductively-Coupled 
Plasma Mass Spectrometer was used to determine metal contents. Confocal microscopic 
images were obtained on glass slides and imaged on the Olympus FlowView500 confocal 
microscope at the UNC-CH Microscope and Imaging Facility. Images were analyzed using 
ImageJ (with the UCSD plugin) and PhotoShop.  
MR images were acquired on a Siemens 3T Allegra (Siemens Medical Systems, 
Erlagen, Germany) with a CP coil. A 3D FLASH sequence was utilized to compute T1 maps 
with seven different flip angles (2, 5, 10, 20, 30, 40, and 60). Imaging parameters were 
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FOV=190 x 190 x 64 mm3, matrix size= 128 x 128 x 32, TR/TE= 40/1.64 ms, total data 
acquisition time was 30 min. The net magnetization from the region of interest of each 
sample was fit using a Marquardt-Levenberg algorithm for multiparametric nonlinear 
regression analysis using MATLAB program. Longitudinal relaxivity, T1 was calculated 
from these data, and r1 was determined from the slope of 1/T1 versus [Gd3+] plot. A 2-D 
multiple echo spin echo sequence was used to estimate T2 maps. In total, 32 echoes with an 
echo spacing of 6.2 ms (the first echo time) were obtained; TR was 3000 ms. FOV and 
matrix size were set to 190 x 190 mm2 and 128 x 128. The slice thickness was 2 mm. The 
total data acquisition time was about 6 minutes and 29 seconds. Transverse relaxivity, r2, was 
determined from the slope of 1/T2 versus [Gd3+] plot. All images were acquired on a 9.4T 
Bruker BioSpec system with a 35 mm quadrature RF transmit and receive coil. 
2.4.2. Synthesis of Reagents 
 Synthesis of [Ru(5,5’-CO2H-bpy)(bpy)2](PF6)2 (carboxylated Ru(bpy)32+ 
derivative). 5,5’-CO2(Et-bpy) and Ru(bpy)2Cl2 were prepared according to a literature 
method.25 Ru(bpy)2Cl2 (1.16g, 2.39 mmol) and 1.45 equivalents of 5,5’-CO2(Et-bpy) (1.04g, 
3.46 mmol) were refluxed under argon in 160 mL of H2O:EtOH (1:1 v/v) for 8 h. After the 
removal of ethanol by rotary evaporation, the complex was precipitated by the addition of 5 
mL of saturated aqueous ammonium hexafluorophosphate. This crude product was filtered 
and washed with ether, then hydrolyzed by reflux under argon in 100 mL of 4M HCl 
overnight. Precipitation was achieved by the addition of 5 mL of saturated aqueous 
ammonium hexafluorophosphate. The product was filtered and washed with water to remove 
excess HCl and washed with ether. Yield: 1.79 g (80%). 1H NMR (DMSO-d6): 8.99 (d, 2H), 
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8.89 (m, 4H), 8.53 (d, 2H), 8.20 (m, 4H), 7.99 (s, 2H), 7.84 (d, 2H), 7.78 (d, 2H), 7.59 (t, 
2H), 7.49 (t, 2H). 
 Synthesis of DOPE-AA. DOPE (50 mg, 0.067 mmol) was reacted with 4-
methoxybenzoic acid (103.5 mg, 0.672 mmol) in dichloromethane (10 mL, anhydrous), in 
the presence of N,N’-dicyclohexylcarbodiimide (27.2 mg, 0.134 mmol) and 4-
dimethylaminopyridine (16.42 mg, 0.134 mmol) under nitrogen. The reaction was stirred at 
room temperature for 24 h in the dark. After the removal of dichloromethane by rotary 
evaporation, the crude product was dissolved in chloroform, and the solution was washed 
with 4% Na2CO3, 0.2M HCl, water, and then dried over MgSO4. The resulting crude product 
was purified by column chromatography using silica gel and 5:1 chloroform/methanol (v/v) 
as the eluent. The product was obtained after removal of the solvents. Yield: 30 mg (51%). 
1H NMR (CDCl3): δ 7.82 (d, J =7.6 Hz, 2H); 6.78 (s, 2H); 5.31 (m, 4H); 3.76 (s, 3H); 2.15 (s, 
4); 1.97 (s, 6H); 1.62 (s, 10H); 1.46 (s, 4H); 1.21 (t, J= 14 Hz, 30H); 0.85 (t, J = 6 Hz, 6H). 
Synthesis of Liposomes. 1:1 (by mol) DSTAP/DOPE liposomes were prepared by 
combining DSTAP (5 mg, 0.007117 mmol) and DOPE (5.295 mg, 0.07117 mmol) in 
chloroform. The solvent was removed under vacuum by rotary evaporation. The resulting 
lipid film was further dried under vacuum then hydrated with 1 mM aq. KCl. The dispersion 
was extruded three times through a 0.6 µm polycarbonate filter membrane and ten times 
through a 0.1 µm polycarbonate filter membrane. The resulting liposome formulation can be 
stored up to 1 week at 4 °C. Liposomes were made to contain DOPE-AA by incorporating 10 
mol% DOPE-AA in the initial chloroform solution.  
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Synthesis of DOPE-FITC. Fluorescein isothiocyanate (FITC, 27.3 mg, 0.07 mmol) 
was added to a small round-bottom flask and dried under high vacuum for 1 h. Anhydrous 
methanol (10 mL) and triethylamine (6.2 µL) were added to the round-bottom flask, followed 
by 0.5 mL DOPE (100 mg/mL, 0.067 mmol in anhydrous dichloromethane). The reaction 
was magnetically stirred under nitrogen gas at room temperature for 5 h in the dark. After the 
removal of solvent by rotary evaporation, the product was redissolved in methanol (77 mg, 
25 mg/mL, 100% yield). 
2.4.3. Synthesis of MTX and Folate-Containing NCPs 
 
  Synthesis of La-MTX NCP. Both LaCl3·7H2O (22.15 mg, 0.0600 mmol) and MTX 
(13.65 mg, 0.0300 mmol) were dissolved in 6 mL DMF containing 5 µL 6M (0.0300 mmol, 
1 eq.) HCl aq. The solution was heated in a sealed microwave vessel at 80 °C for 10 min 
without stirring. The product was isolated from the resulting yellow dispersion by 
centrifugation at 13,000 rpm for 15 min, washed by subsequent sonication and 
centrifugation, with DMF and EtOH, and dispersed in EtOH. 
  Synthesis of Pr-MTX NCP. Both Pr(NO3)3·6H2O (13.36 mg, 0.0300 mmol) and 
MTX (13.65 mg, 0.0300 mmol) were dissolved in 6 mL DMF and heated in a sealed 
microwave vessel at 80 °C for 5 min without stirring. The product was isolated from the 
resulting yellow dispersion by centrifugation at 13,000 rpm for 15 min, washed by 
subsequent sonication and centrifugation, with EtOH, and dispersed in EtOH. 
  Synthesis of Gd-MTX NCP. Both Gd(NO3)3·6H2O (13.54 mg, 0.0300 mmol) and 
MTX (13.63 mg, 0.0300 mmol) were dissolved in 6 mL DMF and the solution was heated in 
a sealed microwave vessel at 80 °C for 5 min without stirring. The product was isolated from 
the resulting yellow dispersion by centrifugation at 13,000 rpm for 15 min, washed by 
59 
 
sonication and centrifugation, with DMF then EtOH, and dispersed in EtOH. Yield: 15.6 mg 
(85%). 
  Synthesis of Gd-Folate NCP. 22.5 mg (0.0498 mmol) Gd(NO3)3·6H2O was 
dissolved in 3 mL DMF, and 22.2 mg (0.0503 mmol) folic acid was dissolved in 7 mL DMF 
by heating at 50 °C. The solution was heated in a sealed microwave vessel at 80 °C for 5 min 
without stirring. The product was isolated from the resulting yellow dispersion by 
centrifugation at 13,000 rpm for 15 min, washed by sonication and centrifugation, with DMF 
then EtOH, and dispersed in EtOH. Yield:  7.5 mg (25.2%). 
  Synthesis of [Ru(5,5’-CO2-bpy)(bpy)2]-doped analogs of Gd-MTX and Gd-
Folate. 10 mol% [Ru(5,5’-CO2-bpy)(bpy)2]-doped Gd-MTX was synthesized by the same 
procedure as Gd-MTX, but with the addition of 2.02 mg (0.00308 mmol, 10 mol%) [Ru(5,5’-
CO2H-bpy)(bpy)2](PF6)2 to the DMF solution. Particles were isolated in a yield of 20.9 mg 
(72%). 10 mol% [Ru(5,5’-CO2-bpy)(bpy)2]-doped Gd-Folate was synthesized by the same 
procedure as Gd-Folate, but with the addition of 3.3 mg (0.0050 mmol, 10 mol%) 
Ru(bpy)2(bby-CO2H) to the DMF solution. Particles were isolated in a yield of 9.45 mg 
(29%). Synthesis of lipid-coated versions of doped Gd-MTX and Gd-Folate were carried out 
by the same methods described above. 
2.4.4.   Lipid-Coating Procedures 
 
 Synthesis of DOTAP/Cholesterol-coated Zr-MTX. Particle dispersions of Zr-MTX 
and 1:1 (by mol) DOTAP/cholesterol liposomes in 1 mM aq. KCl were combined and the 
sample was vortexed and sonicated then isolated by centrifugation at 6,000 rpm for 10 min to 
remove excess liposomes. The lipid-coated sample was dispersed in 1 mM aq. KCl. 
  Synthesis of DSTAP/DOPE-coated Gd-MTX or Gd-Folate. Particle dispersions of 
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Gd-MTX (or Gd-Folate) and 1:1 (by mol) DSTAP/DOPE liposomes in 1 mM aq. KCl were 
heated to 70 °C and mixed together. The dispersion was vortexed and was allowed to sit at 
room temperature for 30 minutes. Empty liposomes were removed by centrifugation at 6,000 
rpm for 10 minutes, and the resulting particles were dispersed in 1 mM aq. KCl by 
sonication. 
  Synthesis of DSTAP/DOPE-AA-coated Gd-MTX or Gd-Folate. These lipid-coated 
NCPs were produced by the same technique as above, but using 1:1 (by mol) DSTAP/DOPE 
liposomes, incorporating 10 mol% DOPE-AA. 
  Release Profiles. An amount of testing material was isolated by centrifugation and 
redispersed in 1 mM aq. KCl. The material was placed in a length of 10K molecular weight 
cutoff cellulose dialysis tubing and submerged in 250 mL 8 mM PBS (pH = 7.4, 37 °C). At 
designated time intervals, 1 mL aliquots were removed from the dialysate and analyzed by 
UV-Vis spectroscopy at 305 nm. 
  PEGylation of Lipid-Coated Gd-MTX By Post-Insertion. PEG2K-DOPE micelles 
were prepared by dissolving PEG-DOPE in 1 mM aq. KCl. Lipid-coated Gd-MTX was 
prepared as described above. The lipid-coated particles were isolated by centrifugation at 
6,000 rpm for 10 min and dispersed in 1 mM aq.KCl. Volumes of DOPE-PEG micelles were 
added resulting in varying mol% PEG-DOPE amounts, and the samples were mixed by 
vortexing. The particles were isolated by centrifugation at 6,000 rpm for 10 min and 
dispersed in 1 mM aq. KCl.  
  PEGylation of Lipid-Coated Gd-MTX By Pre-Insertion. 1:1 (by mol) 
DSTAP/DOPE liposomes containing 5 mol% (or another amount) PEG-DOPE were prepared 
using the procedure described for non-PEGylated liposomes. Gd-MTX nanoparticles were 
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isolated by centrifugation, dispersed in 1 mM aq. KCl, and heated to 70 °C. PEGylated 
liposomes were added to the particles and the dispersion was vortexed and heated at 70 °C 
for 15 min. The lipid-coated particles were centrifuged at 6,000 rpm for 10 min to remove 
empty liposomes, and dispersed in 1 mM aq. KCl. 
  Determination of PEG Coverage By Iodine Assay. It is known that solutions of 
I2/KI react with PEG, resulting in colored I-PEG species that can be assayed by UV-Vis 
spectrometry.33-35 A standard curve of different concentrations (µg/mL) DOPE-PEG2K was 
assembled by dissolving different amounts of DOPE-PEG2K in aqueous solution containing 5 
% (w/v) BaCl2 in 1 N HCl and amounts of 10 g/L I2 and 20 g/L KI. A maximum absorbance 
is observed at 500 nm (Figure 2.43) and is converted into a standard curve (Figure 2.44): 
Abs500 nm = 0.0507(DOPE-Peg2K, µg/mL)-0.0383. 
 
Figure 2.43. UV-Vis spectrum of DOPE-Peg2K in a solution of I2/KI, showing a maximum 
absorbance at ~460 nm. 500 nm was used as the standard curve absorbance to reduce any 
interference from other species in solution. 
350 450 550 650
A
bs
or
ba
nc
e
Wavelength (nm)
62 
 
 
 
Figure 2.44. Standard curve at 500 nm for different concentrations of DOPE-Peg2K in I2/KI, 
BaCl2 in 1 N HCl. 
 
 
  Samples of PEGylated Gd-MTX@Lipid for PEG content analysis were prepared by 
adding 0.5 mL of NCP dispersion to 1.5 mL H2O, 0.5 mL BaCl2 in 1 N HCl, and 37.5 µL aq. 
10 g/L I2 and 20 g/L KI. The samples were assayed by UV-Vis, and the absorbance at 500 
nm was converted to µg/mL DOPE-Peg2K. The concentration of DOPE-Peg2K was converted 
into wt% DOPE-Peg2K and PEG coverage in nm2/PEG by the following theoretical 
calculation, assuming 5 wt% lipid bilayer, NCP diameter = 120 nm, NCP density (D) = 1 
g/cm3, molecular weight (mw) DOPE-PEG2K = 2800 g/mol: 
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2.4.5.   In Vitro Assay Methods 
 
 Cell Lines. CCRF-CEM acute lymphoblastic leukemia cells (ATCC# CCL-119) and 
Jurkat acute lymphoblastic leukemia cells (ATCC# TIB-152) were purchased from the 
Tissue Culture Facility of Lineberger Comprehensive Cancer Center at the University of 
North Carolina at Chapel Hill. Both cell lines were maintained as a suspension in RPMI-
1640 growth medium (Cellgro) supplemented with 10% fetal bovine serum (Sigma) and 2% 
penicillin-streptomycin (Sigma). 
 Cytotoxicity Assays Against CCRF-CEM Cells.  For the 3 h assay: confluent 
CCRF-CEM cells were isolated by centrifugation, dispersed in fresh RPMI-1640 media, and 
cell density determined by a hemocytometer. Cells were plated in 6-well plates at a cell 
density of 1 x 106 cells/well in 1.5 mL RPMI-1640 medium and incubated overnight at 37 °C 
and 5% CO2. Aliquots of MTX or Zr-MTX particles in medium were added to the wells for 
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MTX concentrations (in µM) of 0, 5, 12.5, 25, 50, and 100. Plates were incubated (37 °C, 5% 
CO2) for 3 h. Viability was determined by the trypan blue exclusion assay. 
 For the 48 h assay: confluent CCRF-CEM cells were isolated by centrifugation, 
dispersed in fresh RPMI-1640 media, and cell density determined by a hemocytometer. Cells 
were plated in 6-well plates at a cell density of 5 x 104 cells/well in 1.5 mL RPMI-1640 
medium and incubated overnight at 37 °C and 5% CO2. Aliquots of MTX or Zr-MTX 
particles in medium were added to the wells for MTX concentrations (in µM) of 0, 5, 12.5, 
25, 50, and 100. Plates were incubated (37 °C, 5% CO2) for 48 h. Viability was determined 
by the trypan blue exclusion assay. 
  Cytotoxicity Assays Against Jurkat Cells. Confluent Jurkat cells were counted from 
the culture flask by hemocytometer. Cells were plated in 6-well plates at a cell density of 5 x 
104 cells/well in 1.5 mL RPMI-1640 complete growth medium. The cells were incubated at 
37 °C and 5% CO2 overnight. MTX and particle dispersions of Gd-MTX and lipid-coated 
Gd-MTX (16 µM) in RPMI-1640 media and additional media were added to wells, resulting 
in MTX concentrations (µM) of 0, 0.25, 0.5, 1, 2, and 4. Cells were incubated (37 °C, 5% 
CO2) with free MTX or particle for 48 h or for 72 h. Viability was determined by the trypan 
blue exclusion assay. 
  Viability Control Assays with Jurkat Cells. This assay was conducted to show that 
MTX is the only contributor to cytotoxicity and that Gd(III) has no bearing on the 
cytotoxicity. Gd(NO3)3, Gd-Folate, and lipid-coated Gd-Folate formulations were tested 
against Jurkat acute lymphoblastic leukemia cells. Confluent Jurkat cells were counted from 
the culture flask by hemocytometer. Cells were plated in 6-well plates at a cell density of 5 x 
104 cells/well in 1.5 mL RPMI-1640 complete growth medium. The cells were incubated at 
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37 °C and 5% CO2 overnight. Free Gd(III) and particle dispersions (200 µM) in RPMI-1640 
media and additional media were added to wells, resulting in folate concentrations (µM) of 0, 
0.5, 1, 2.5, 5, and 10. Cells were incubated (37 °C, 5% CO2) with free Gd(III) salt or particles 
for 48 h. Viability was determined by the trypan blue exclusion assay. 
  Confocal Microscopy of [Ru(5,5’-CO2-bpy)(bpy)2]-doped Analogs of Gd-MTX 
and Gd-Folate. Wells in 6-well plates were seeded with 500,000 cells and 2 mL total of 
RPMI-1640 media (10% FBS, 2% penicillin-streptomycin). The plates were incubated for 24 
h at 37 °C and 5% CO2. Particle dispersions were prepared in RPMI-1640 medium, and 
aliquots of particle dispersions/additional media were added to the wells, resulting in a 
concentration of 0.04 mg/well for each particle. The cells were incubated with particles for 1 
h, and cell suspensions were centrifuged. Cell pellets were re-suspended in PBS, 15 µL 
AnnexinV FITC conjugate was added, and the cells were allowed to sit at room temperature 
for 10 min. The cells were centrifuged and redispersed in 20µL of media. The entire cell 
suspension was placed on glass coverslips, adhered on glass slides with antifade mounting 
medium, and imaged at the UNC-CH Microscope and Imaging Facility. 
 
 
 
 
 
 
 
 
66 
 
2.5. References 
(1) Davis, M. E.; Chen, Z.; Shin, D. M. Nat. Rev. Drug Discov. 2008, 7, 771. 
 
(2) Krajinovic, M.; Moghrabi, A. Pharmacogenomics 2004, 5, 819. 
 
(3) Chen, Y.-H.; Tsai, C.-Y.; Huang, P.-Y.; Chang, M.-Y.; Cheng, P.-C.; Chou, C.-H.; 
Chen, D.-H.; Wang, C.-R.; Shiau, A.-L.; Wu, C.-L. Mol. Pharmaceutics 2007, 4, 713. 
 
(4) Dhanikula, R. S.; Argaw, A.; Bouchard, J.-F.; Hildgen, P. Mol. Pharmaceutics 2008, 
5, 105. 
 
(5) Kohler, N.; Sun, C.; Wang, J.; Zhnag, M. Langmuir 2005, 21, 8858. 
 
(6) Kohler, N.; Sun, C.; Fichtenholtz, A.; Gunn, J.; Fang, C.; Zhang, M. Small 2006, 21, 
785. 
 
(7) Wosikowski, K.; Biedermann, E.; Rattel, B.; Breiter, N.; Jank, P.; Loser, R.; Jansen, 
G.; Peters, G. J. Clin. Cancer Res. 2003, 9, 1917. 
 
(8) Yang, X.; Zhang, Q.; Wang, H.; Chen, H.; Zhang, F.; Gao, F.; Liu, L. Colloids Surf. 
B 2008, 61, 125. 
 
(9) deKrafft, K. E., Nanoscale Coordination Polymers for Biomedical Applications and 
Hybrid Materials for Solar Fuel Catalysis. Ph.D. Dissertation, University of North 
Carolina, Chapel Hill, 2012.  
 
(10) Cavka, J. H.; Jakobsen, S.; Olsbye, U.; Guillou, N. L.; Bordiga, C. S.; Lillerud, K. P. 
J. Am. Chem. Soc. 2008, 130, 13850. 
 
(11) Stathopoulos, G. P. Anticancer Drugs 2010, 21, 732. 
 
(12) Li, J.; Chen, Y.-C.; Tseng, Y.-C.; Mozumdar, S.; Huang, L. J. Controlled Release 
2010, 142, 416. 
 
(13) Liu, D.; Kramer, S. A.; Huxford-Phillips, R. C.; Wang, S.; Della Rocca, J.; Lin, W. 
Chem. Commun. 2012, 48, 2668. 
 
(14) van Schooneveld, M. M.; Vucic, E.; Koole, R.; Zhou, Y.; Stocks, J.; Cormode, D. P.; 
Tang, C. Y.; Gordon, R. E.; Nicolay, K.; Meijerink, A.; Fayad, Z. A.; Mulder, W. J. 
M. Nano Lett. 2008, 8, 2517. 
 
(15) Troutier, A.-L.; Delair, T.; Pichot, C.; Ladavire, C. Langmuir 2005, 21, 1305. 
 
(16) Olson, F.; Hunt, C. A.; Szoka, F. C.; Vail, W. J.; Papahadjopoulos, D. Biochim. 
Biophys. Acta 1979, 557, 9. 
67 
 
 
 
(17) Ashley, C. E.; Carnes, E. C.; Phillips, G. K.; Padilla, D.; Durfee, P. N.; Brown, P. A.; 
Hanna, T. N.; Liu, J.; Phillips, B.; Carter, M. B.; Carroll, N. J.; Jiang, X.; Dunphy, D. 
R.; Willman, C. L.; Petsev, D. N.; Evans, D. G.; Parikh, A. N.; Chackerian, B. W.; 
Peabody, D. S.; Brinker, C. J. Nat. Mater. 2011, 10, 389. 
  
(18) Liu, J.; Stace-Naughton, A.; Jiang, X.; Brinker, C. J. J. Am. Chem. Soc. 2009, 131, 
1354. 
 
(19) Vilner, B. J.; John, C. S.; Bowen, W. D. Cancer Res. 1995, 55, 408. 
 
(20) Aydar, E.; Palmer, C. P.; Djamgoz, B. A. Cancer Res. 2004, 64, 5029. 
 
(21) Banerjee, R.; Tyagi, P.; Li, S.; Huang, L. Int. J. Cancer 2004, 112, 693. 
 
(22) John, C. S.; Vilner, B. J.; Geyer, B. C.; Moody, T.; Bowen, W. D. Cancer Res. 1999, 
59, 4578. 
 
(23) Ganapathy, M. E.; Prasad, P. D.; Huang, W.; Seth, P.; Leibach, F. H.; Ganapathy, V. 
J. Pharmacol. Exp. Ther. 1999, 289, 251. 
 
(24) Cobos, E. J.; Entrena, J. M.; Nieto, F. R.; Cendan, C. M.; Del Pozo, E. Curr. 
Neuropharmacol. 2008, 6, 344. 
 
(25) Liu, D.; Huxford, R. C.; Lin, W. Angew. Chem. Int. Ed. 2011, 50, 3696. 
 
(26) Papahadjopoulous, D.; Allen, T. M.; Gabizon, A.; Mayhew, E.; Matthay, K.; Huang, 
S. K.; Lee, K. D.; Woodle, M. C.; Lasic, D. D.; Redemann, C.; Martin, F. J. Proc. 
Natl. Acad. Sci. USA 1991, 88, 11460. 
 
(27) Woodle, M. C.; Lasic, D. D. Biochim. Biophys. Acta 1992, 1113, 171. 
 
(28) Gabizon, A.; Catane, R.; Uziely, B.; Kaufman, B.; Safra, T.; Cohen, R.; Martin, F.; 
Huang, A.; Barenholz, Y. Cancer Res. 1994, 54, 987. 
 
(29) Lasic, D.; Martin, F. Stealth Liposomes; CRC Press: Boca Raton, FL, 1995. 
 
(30) Klibanov, A. L.; Maruyama, K.; Torchilin, V. P.; Huang, L. FEBS Lett. 1990, 268, 
235. 
 
(31) Uster, P. S.; Allen, T. M.; Daniel, B. E.; Mendez, C. J.; Newman, M. S.; Zhu, G. Z. 
FEBS Lett. 1996, 386, 243. 
 
(32) Li, S.-D.; Huang, L. Biochim. Biophys. Acta 2009, 1788, 2259. 
 
68 
 
(33) Sims, G. E. C.; Snape, T. J. Anal. Biochem. 1980, 107, 60. 
 
(34) Guttman, D. E.; Higuchi, T. J. Am. Pharm. Assoc. 1956, 45, 668. 
 
(35) Chang, J.-H.; Ohno, M.; Esumi, K.; Meguro, K. J. Am .Oil Chem. Soc. 1988, 65, 
1664. 
 
 
 
 
 
 
 
 
 
CHAPTER 3 
 
Hafnium-Based Nanoscale Coordination Polymers for Delivery of Pemetrexed 
 
 
3.1. Introduction 
 3.1.1. Pemetrexed 
Pemetrexed (PMX) is an antifolate chemotherapeutic (Figure 3.1) that works by 
inhibiting multiple enzyme targets in the folic acid pathway and ultimately aiding in 
apoptotic cell death.1,2 This antifolate is used alone or in combination with cisplatin for 
treatment of non-small cell lung cancer (NSCLC) and is currently being surveyed for use in 
the treatment of other tumor types.3-5 Even though PMX is a very potent chemotherapeutic, 
this efficacy comes packaged with a multitude of side effects resulting from high doses such 
as mucositis, hematological toxicity, and increased risk of infection.2,5 Considering the 
drawbacks that come with all small molecule chemotherapy drugs, PMX is an ideal candidate 
for incorporation into an NCP. Similarly to methotrexate, PMX possesses two carboxylate 
groups that can be used for coordination to a binding metal. To the best of our knowledge, no 
nanoscale drug delivery vehicles for the delivery of PMX have been reported.  
This chapter presents the synthesis and characterization of PMX-containing NCPs. 
Hf-PMX particles (19.7 wt% PMX) were stabilized by addition of a lipid bilayer and 
rendered an active targeting agent via incorporation of an anisamide-lipid conjugate. This 
formulation was shown to have greater efficacy against free PMX in in vitro cytotoxicity 
assays against two NSCLC cell lines. 
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Figure 3.1. Structure of the antifolate pemetrexed (PMX).  
  
3.2. Results and Discussion 
 3.2.1. UV-Visible Analysis – Pemetrexed 
 Like methotrexate, PMX can be detected by UV-Vis spectroscopy (Figure 3.2); the 
UV-Vis spectrum of PMX is however highly pH dependent.6 Two standard curves were 
prepared: one using 8 mM PBS for Zr- or Gd-PMX NCP analysis (Absorbance225 nm = 
0.0155(µM PMX) – 0.0007) and another using 0.1 M H3PO4 for Hf-PMX analysis 
(Absorbance285 nm = 0.0053(µM PMX) + 0.0049). These UV-Vis standard equations were 
used for analysis of PMX for drug loading data and release profiles. 
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Figure 3.2. UV-Vis plots of PMX in (a) 8 mM PBS and (b) 0.1 M H3PO4, both media used 
for generating standard curves for PMX concentrations. 
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3.2.2. Synthesis and Characterization of Mn-PMX NCP 
 Crystalline particles of Mn-PMX were prepared by a surfactant-templated heating 
method in which MnCl2·4H2O and Na2PMX were reacted in a reverse microemulsion (W = 
15) with 0.1 M CTAB/0.5 M 1-hexanol in isooctanes at 80 °C for 20 min. Rod-like particles 
~1 µm long and ~200 nm wide by SEM (Figure 3.3) were produced. These particles have a ζ 
potential of -22.3 mV, indicating that these NCPs are carboxylate-terminated and can 
potentially be lipid-coated by mixing with cationic liposomes. Mn-PMX possesses crystalline 
attributes by PXRD (Figure 3.4). Attempts to synthesize a single crystal for determination of 
a structure by X-ray diffraction were unsuccessful. These particles have a very high PMX 
drug loading by TGA, 69.9 wt%, and Mn-PMX has a 3:1 Mn:PMX molar ratio (Figure 3.5). 
These particles aggregate heavily in aqueous media, thus precluding their stabilization by 
lipid coating.  
  
Figure 3.3. SEM micrographs of crystalline, rod-like Mn-PMX NCPs.  
 
 
 
 
 
a) b) 
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Figure 3.4. PXRD pattern of Mn-PMX nanorods.  
 
 
 
Figure 3.5. TGA of Mn-PMX showing PMX organic weight loss (69.9 wt% PMX) between 
275 and 400 °C. TGA of PMX is shown for comparison. 
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 3.2.3. Synthesis and Characterization of Zr-PMX NCP 
 Amorphous particles of Zr-PMX were synthesized by a solvothermal synthesis in 
which anhydrous ZrCl4 and Na2PMX were heated in 5 % v/v H2O in DMF at 60 °C for 5 
min. The resulting blue particles (yield = 85.8 %) are between 250-300 nm by SEM (Figure 
3.6) and 273.3 nm (Z average diameter) with a PDI of 0.069 by DLS. Zr-PMX possesses an 
extremely high PMX drug loading of 60.0 wt% by TGA (Figure 3.7). This drug loading is 
further supported by the low Zr content of the particles by ICP-MS. Several attempts were 
made to decrease the size of Zr-PMX, but without success. Additionally, considering the 
previous issues experienced with stabilization of Zr-MTX, it was decided to pursue synthesis 
of PMX-containing NCPs using a trivalent lanthanide as the binding metal. 
 
Figure 3.6. SEM micrograph of Zr-PMX NCPs. 
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Figure 3.7. TGA plot of Zr-PMX NCPs where the organic weight loss yields high PMX 
loading of 60.0 wt% between 275 and 450 °C. 
 
 
 3.2.4. Synthesis and Characterization of Gd-PMX NCP 
Gd-PMX Synthesized by a Solvothermal Method. Particles of Gd-PMX were 
prepared using PMX instead of Na2PMX. PMX was prepared by acidifying Na2PMX by 
dissolving in H2O, precipitating with 1 M aq. HCl, isolating by centrifugation then drying 
under vacuum. Gd-PMX was synthesized by a solvothermal technique in which 
Gd(NO3)3·6H2O and PMX were dissolved in DMF and heated at 80 °C for 5 min to afford a 
brown product. Particles are spherical and between 100-200 nm in diameter by SEM (Figure 
3.8) with a Z average diameter of 126.9 nm and PDI of 0.027 by DLS. With a ζ potential of -
8.37 mV in 1 mM aq. KCl, these particles are ideal for further stabilization by use of 
liposome encapsulation. Gd-PMX is 65.0 wt% PMX by TGA with a 3:2 Gd:PMX molar ratio 
(Figure 3.9). This data is further supported by 13.3 wt% Gd by ICP-MS. Digestion of these 
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Gd-PMX NCPs in 15 mg/mL Na2EDTA shows that the UV-Vis spectrum has been altered 
significantly from free PMX (Figure 3.10). We speculate that the oxidizing power of 
lanthanide nitrates (like Gd(NO3)3 used in the synthesis of Gd-PMX) may degrade PMX 
under these synthetic conditions. Thus, we sought to synthesize Gd-PMX NCPs using milder 
conditions, such as a surfactant-templated technique. 
 
Figure 3.8. SEM micrograph of Gd-MTX NCPs formed by solvothermal synthesis. 
 
Figure 3.9. TGA plot of Gd-PMX NCPs synthesized by solvothermal synthesis showing 
weight loss corresponding to 65.0 wt% PMX drug loading between 300 and 450 °C. 
0
20
40
60
80
100
0 100 200 300 400 500 600
W
ei
gh
t %
Temperature (°C)
77 
 
 
 
Figure 3.10. UV-Vis plot of digested Gd-PMX NCPs synthesized by a solvothermal 
synthesis, compared to free PMX at the same pH.  
 
 
 Smaller particles of Gd-PMX were prepared by a surfactant-assisted method (W = 15) 
in which aqueous nanodroplets of Gd(NO3)3·6H2O and Na2PMX in a 0.1 M CTAB/0.5 M 1-
hexanol in isooctanes organic phase were heated at 80 °C for 20 min. The resulting white 
product was between 20-50 nm in diameter by SEM and TEM (Figure 3.11) with a Z average 
diameter of 88.9 nm and a PDI of 0.158 in EtOH. The Gd-PMX particles have a ζ potential 
of -5.68 mV in 1 mM aq. KCl, and are not as anionic as previous NCP systems. The particles 
have a high PMX loading of 72.3 wt% by TGA (Figure 3.12), a drug loading that is 
supported by the low Gd content obtained by ICP-MS (11.7 wt%). 
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Figure 3.11. SEM (a) and TEM (b) micrographs of Gd-PMX NCPs synthesized by a 
surfactant-assisted heating technique. 
 
 
Figure 3.12. TGA plot of Gd-PMX synthesized by a surfactant-templated synthesis showing 
organic weight loss corresponding to 72.3 wt% PMX drug loading between 300 and 450 °C. 
 
 
Digestion of these particles in 15 mg/mL Na2EDTA aq. and analysis by UV-Vis 
shows that the spectrum for the digested particles matches that of free PMX (Figure 3.13). 
This indicates that the PMX drug does not degrade during NCP synthesis. The use of Gd(III) 
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ions in this material makes this material a good candidate as a MRI contrast enhancement 
agent. As shown in Figure 3.14, Gd-PMX has moderate r1 and r2 values, 4.254 mM-1s-1 and 
13.943 mM-1s-1, respectively.  
Stabilization of these NCPs was attempted by encapsulation within a 1:1 (by mol) 
DSTAP/DOPE lipid bilayer. Addition of increasing amounts of liposomes in 1 mM aq. KCl 
shows alleviation in aggregation as well as a shift from neutral to highly cationic ζ potentials 
(Figure 3.15). Despite these promising results, the PDI values remain large (indicating a 
polydisperse sample) and the lipid coating procedure could not be replicated. 
 
Figure 3.13. UV-Vis plot of Gd-PMX NCPs synthesized by the surfactant-assisted heating 
method, compared to free PMX showing that the PMX incorporated in the NCP has not 
degraded.  
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Figure 3.14. MR relaxivity plot for Gd-PMX (surfactant-templated) showing values for r1 
and r2. 
 
Figure 3.15. DLS Z average and ζ potential plots of Gd-PMX coated with increasing 
amounts of 1:1 (by mol) DSTAP/DOPE liposomes showing decreased particle aggregation 
and cationic ζ potentials with increased liposome volumes. 
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 3.2.5. Synthesis and Characterization of Hf-PMX NCP 
 We sought to use Hf(IV) as the binding metal for PMX-containing NCPs as hafnium 
oxide is known to be an efficient radiotherapy agent.7 The combination of PMX and Hf(IV) 
in an NCP would render this material a dual therapy: a radiotherapeutic with use of Hf(IV) 
and a chemotherapeutic with incorporation of PMX. 
Particles of Hf-PMX were prepared by a solvothermal synthesis in which HfCl4, 
Na2PMX, and DOPA (a lipid-based capping agent) were heated in DMF at 80 °C for 10 min. 
These particles are slightly fused and between 200-400 nm in diameter by SEM (Figure 3.16) 
with a number average diameter of 563.5 nm and PDI of 0.585 by DLS in THF.  
 
Figure 3.16. SEM micrograph of Hf-PMX NCPs synthesized by a solvothermal method. 
 
TGA gives a PMX drug loading of 40.0 wt% (Figure 3.17). The large amount of 
inorganic weight remaining indicates that it is likely that these particles contain a large 
amount of hafnium oxide. Due to the large size of these particles and lack of dispersibility in 
THF (dispersibility in an organic solvent allows for stabilization by addition of a lipid layer 
incorporated in the DOPA surface capping agent), we moved to formulate smaller DOPA-
capped Hf-PMX NCPs that are dispersible in organic solvent. Smaller particles of DOPA- 
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capped Hf-PMX were prepared by a reverse microemulsion (W = 7.4) using aqueous 
solutions of HfOCl2·8H2O and Na2PMX dispersed in 0.3 M TritonX-100/1.5 M 1-hexanol in 
cyclohexane, with the addition of DOPA after 1 h of stirring at room temperature. The 
particles are spherical and <50 nm by TEM (Figure 3.18) with a Z average diameter of 92.6 
nm and PDI of 0.114 in THF, indicating successful capping with DOPA. 
 
Figure 3.17. TGA plot of Hf-PMX synthesized by a solvothermal synthesis showing 40.0 
wt% PMX drug loading. 
 
  
Figure 3.18. TEM micrograph of DOPA-capped Hf-PMX NCPs. 
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PMX drug loading of these particles is 19.7 wt% as determined by UV-Vis analysis 
of digested particles in 0.1 M H3PO4 (Absorbance285 nm = 0.0053(µM PMX) + 0.0049); 
though this loading may be low when compared to other NCP materials, 19.7 wt% PMX is 
reasonable as PMX is a very potent anticancer agent. TGA of DOPA-capped Hf-PMX shows 
a large amount of organic weight which can be attributed to DOPA incorporated with the 
particles (Figure 3.19). It is assumed that all of the DOPA is bound to the NCP as the 
particles are subsequently washed and centrifuged with cyclohexane and THF. A release 
profile of Hf-PMX in 5 mM PBS at 37 °C reveals that the particles are unstable in phosphate 
buffer with a t1/2 ~ 15 min. This experiment shows that need for this material to be further 
stabilized with addition of a lipid layer. 
 
Figure 3.19. TGA plot of DOPA-capped Hf-PMX NCPs, showing organic weight loss 
attributed to DOPA and PMX. 
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 3.2.6. Lipid Coating of Hf-PMX NCP 
 A simultaneous lipid coating and PEGylation procedure was done to try to stabilize 
the DOPA-capped Hf-PMX NCPs based on a previously-reported method.8 The first attempt 
involved forming a dispersion of Hf-PMX particles with cholesterol, DOPC, and DSPE-
Peg2K in THF. This dispersion was added dropwise to a stirring volume of H2O at 50 °C, and 
the THF was removed with a N2 stream. The resulting lipid-coated NCPs had a Z average 
diameter of 120.4 nm and a PDI of 0.159 by DLS. Despite these promising results, this 
procedure did not enhance stability of the NCP nor could it be replicated consistently. 
However, when the lipid-coated formulation was prepared in 30 % v/v EtOH/H2O instead of 
only H2O, the resulting NCPs were more stable than the as-synthesized ones. These lipid-
coated Hf-PMX particles did not differ in size or morphology from the as-synthesized NCPs 
by TEM  (Figure 3.20) and had a Z average diameter of 135.9 nm with a PDI of 0.199. A 
release profile in 5 mM PBS at 37 °C showed that Hf-PMX lipid-coated with the procedure 
had a t1/2 ~ 3 h compared to 15 min for the as-synthesized particles (Figure 3.21). We believe 
that more stable NCPs result from using 30 % v/v EtOH/H2O because EtOH is important to 
ensure dispersibility of the as-synthesized particles as lipid coating occurs. 
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Figure 3.20. TEM micrograph of lipid-coated Hf-PMX NCPs. 
 
Figure 3.21. Release profile of DOPA-capped Hf-PMX (t1/2 ~ 15 min) and Lipid-coated Hf-
PMX (t1/2 ~ 3 h) in 8 mM PBS at 37 °C showing stabilization with a lipid bilayer. 
 
 
Stability was also demonstrated by observing the changes in diameter and PDI over 
18 h in 5 mg/mL bovine serum albumin (BSA) in 5 mM PBS. Albumin is a blood protein 
used known to bind and aggregate poorly-PEGylated particles in the bloodstream. Stability is 
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assessed by observing little to no change of particle diameter as the particles are exposed to 
BSA over several hours. Over ~18 h, a 20 nm decrease in Z average is observed, likely due 
to the eventual settling out of larger particles (Figure 3.22). No aggregation or increase in 
particle diameter or PDI is observed, further establishing that the lipid-coated particles are 
stable under these conditions. 
 
Figure 3.22. BSA assay testing the stability of lipid-coated Hf-PMX for 18 h. 
 
Lipid-coated Hf-PMX was doped with a small amount (10 mol% of DSPE-Peg2K) of 
DSPE-Peg2K-AA, to afford a formulation that actively targets sigma receptors which are 
overexpressed in a number of epithelial cancer tissues.9-13 This formulation was prepared by 
the same method as the non-targeted particles, but with the addition of both DSPE-Peg2K and 
DSPE-Peg2K-AA instead of only DSPE-Peg2K in the lipid formulation. The resulting particles 
are the same size and morphology as the non-targeted formulation by TEM (Figure 3.23) 
with a Z average diameter of 134.5 nm and PDI of 0.334. 
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Figure 3.23. TEM micrograph of Hf-PMX@Lipid-AA NCPs. 
 
3.2.7. Synthesis and Characterization of Hf-Folate NCP 
Control vehicles using folic acid as the ligand instead of cytotoxic PMX were 
prepared by a solvothermal synthesis in which folic acid and HfOCl2·8H2O were heated at 80 
°C in DMF in the presence of H3PO4 aq. The resulting particles have a Z average diameter of 
128.6 nm and PDI of 0.136 in EtOH and are between 50 and 150 nm by TEM (Figure 3.24). 
These NCPs, Hf-Folate, are ~34 wt% folic acid by TGA (Figure 3.25). 
 
Figure 3.24. TEM micrograph of Hf-Folate control vehicles. 
88 
 
 
Figure 3.25. TGA of Hf-Folate NCPs showing 34 wt% folic acid organic weight loss 
between 300 and 500 °C. 
 
 
The Hf-Folate NCPs were capped with DOPA by stirring a suspension of NCPs in an 
EtOH/CHCl3 mixture with DOPA for 2 h at room temperature. The resulting DOPA-capped 
NCPs do not differ in size or morphology from the as-synthesized particles by SEM (Figure 
3.26) or DLS (Z average diameter of 144.7 nm and PDI of 0.095 in THF). The DOPA-
capped Hf-Folate control vehicles can be encapsulated in a lipid layer with 
cholesterol/DOPC/DSPE-Peg2K by the same method used for lipid coating of Hf-PMX. The 
resulting Hf-Folate@Lipid NCPs have a Z average diameter of 135.6 nm and PDI of 0.299 in 
5 mM PBS. Additionally, the Hf-Folate control vehicles were targeted with DSPE-Peg2K-AA 
using the same procedure for Hf-PMX. These particles have a Z average diameter of 116.7 
nm and PDI of 0.276. 
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Figure 3.26. SEM micrograph of DOPA-capped Hf-Folate NCPs. 
 
 3.2.8. In Vitro Cytotoxicity Assays 
 Gd-PMX particles formed by the surfactant-templated method were tested in vitro 
against A549 non-small cell lung cancer cells and compared to the efficacy of free PMX. 
Cells were incubated with Gd-PMX or free PMX for 48 h and viability was determined by 
the trypan blue exclusion assay. IC50 values of both free PMX and the NCPs were similar 
with values of 0.75 µM and 1.0 µM, respectively (Figure 3.27). This means that the Gd-PMX 
particles degrade in cell medium and essentially are the equivalent of free PMX. 
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Figure 3.27. In vitro cytotoxicity curves of free PMX and Gd-PMX (by surfactant-assisted 
synthesis) showing equal cytotoxicity over 48 h for both agents. 
 
 
Hf-PMX and the lipid-coated formulations of these NCPs were tested in vitro against 
two NSCLC cell lines. The NCI-H460 line, which overexpresses sigma receptors were tested 
to delve into the cytotoxic effect of this formulation as well as the efficiency of the AA 
targeting ligand. Over 48 h, enhanced efficacy from the targeted formulation was observed 
(Figure 3.28) compared to both the other formulations as well as free PMX. IC50 values were 
free PMX = 170 ± 10 nM, Hf-PMX = 200 ± 14 nM, Hf-PMX@Lipid = 195 ± 7 nM, and Hf-
PMX@Lipid-AA = 63 ± 5 nM. The t test shows that there is a statistically significant 
difference between the IC50 values for Hf-PMX@Lipid and Hf-PMX@Lipid-AA with α = 
0.087 (≤ 0.1). 
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Figure 3.28. IC50 curves of Hf-PMX formulations against the NCI-H460 NSCLC cell line, 
showing enhanced efficacy from the AA-targeted formulation. 
 
 
Additionally, the Hf-PMX formulations were tested in vitro against the A549 NSCLC 
cell line. This cell line expresses sigma receptors in very low amounts, so this 48 h assay was 
used as a control to show that efficacy of the AA-targeted formulation is not enhanced 
(Figure 3.29). The AA-targeted formulation and the nontargeted formulation possess similar 
IC50 values of 467 ± 58 nM and 497 ± 12 nM, respectively. The as-synthesized Hf-PMX 
(IC50 = 400 ± 44 nM) and free PMX (IC50 = 503 ± 25 nM) had similar cytotoxicity to the 
other formulations. The t test shows that there is not a statistically significant difference 
between the IC50 values for Hf-PMX@Lipid and Hf-PMX@Lipid-AA with α = 0.20 (>0.05). 
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Figure 3.29. IC50 curves of Hf-PMX formulations against the A549 NSCLC cell line, 
showing the same efficacy for both lipid-coated formulations. 
 
 
3.3. Conclusion 
NCPs containing the antifolate chemotherapeutic agent PMX were synthesized using 
different binding metals. Zr-based materials could not be stabilized by the addition of a lipid 
bilayer, and Gd-based materials showed that PMX had degraded during synthesis, thus 
compromising its efficacy. However, Hf-based NCPs containing 19.7 wt% PMX could be 
further stabilized by a lipid coating and showed improved in vitro efficacy against two 
NSCLC cell lines. Enhanced efficacy was observed for formulations containing the sigma 
receptor target, anisamide.  
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3.4. Experimental Details 
 3.4.1. Materials and Methods 
 All chemicals, unless otherwise noted, were purchased from Fisher or Sigma Aldrich 
and used without further purification. Pemetrexed was purchased from Shanghai Sunny 
Chemicals (China). 1,2-stearoyl-3-trimethylammonium propane, chloride salt (DSTAP), 1,2-
dioleoyl-sn-glycero-3-phosphate (DOPA), 1,2-dioleoyl-sn-glycero-3-phosphocholine 
(DOPC), and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(polyethylene glycol) 
(DSPE-Peg2K) were purchased from Avanti Polar Lipids. L-α-phosphatidylethanolamine, 
dioleoyl (DOPE) was a gift from Sigma Aldrich. Cell culture supplies, fetal bovine serum 
(Sigma), RPMI-1640 growth medium (Gibco), penicillin-streptomycin (Sigma), and 
phosphate buffered saline (Gibco) were purchased from the Tissue Culture Facility in the 
Lineberger Cancer Center at UNC-Chapel Hill.  
Microwave reactions were carried out in a CEM Discovery or CEM MARS 5 
microwave. Scanning electron microscopy (SEM) was performed with a Hitachi 4700 Field 
Emission Scanning Electron Microscope, and transmission electron microscopy (TEM) was 
performed with a JEM 100CX-II Transmission Electron Microscope. A Cressington 108 
Auto Sputter Coater equipped with a Au/Pd (80/20) target and MTM-10 thickness monitor 
was used to coat samples before SEM imaging. SEM micrographs were obtained on glass 
slides, and TEM micrographs were obtained on carbon-coated copper grids.  
Thermogravimetric analysis (TGA) was done on a Shimadzu TGA-50 equipped with a 
platinum pan, and samples were heated at a rate of 3°C/min under air. Powder x-ray 
diffraction (PXRD) data was gathered on a Bruker SMART APEX II diffractometer using Cu 
radiation, and powder patterns were analyzed with the APEX II package using the phase ID 
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plugin. UV-Vis absorption spectra were obtained using a Shimadzu UV-2401 PC UV-Vis 
recording spectrophotometer. Size and zeta potential information was obtained on a Malvern 
ZetaSizer dynamic light scattering instrument. A Varian 820-MS Inductively-Coupled 
Plasma Mass Spectrometer was used to determine metal contents. 
MR images were acquired on a Siemens 3T Allegra (Siemens Medical Systems, 
Erlagen, Germany) with a CP coil. A 3D FLASH sequence was utilized to compute T1 maps 
with seven different flip angles (2, 5, 10, 20, 30, 40, and 60). Imaging parameters were 
FOV=190 x 190 x 64 mm3, matrix size= 128 x 128 x 32, TR/TE= 40/1.64 ms, total data 
acquisition time was 30 min. The net magnetization from the region of interest of each 
sample was fit using a Marquardt-Levenberg algorithm for multiparametric nonlinear 
regression analysis using MATLAB program. Longitudinal relaxivity, T1 was calculated 
from these data, and r1 was determined from the slope of 1/T1 versus [Gd3+] plot. A 2-D 
multiple echo spin echo sequence was used to estimate T2 maps. In total, 32 echoes with an 
echo spacing of 6.2 ms (the first echo time) were obtained; TR was 3000 ms. FOV and 
matrix size were set to 190 x 190 mm2 and 128 x 128. The slice thickness was 2 mm. The 
total data acquisition time was about 6 minutes and 29 seconds. Transverse relaxivity, r2, was 
determined from the slope of 1/T2 versus [Gd3+] plot. All images were acquired on a 9.4T 
Bruker BioSpec system with a 35 mm quadrature RF transmit and receive coil. 
3.4.2. Synthesis of Reagents 
Synthesis of DSPE-Peg2K-AA. 4-methoxybenzoic acid (3 g, 20 mmol) in 10 mL 
thionyl chloride was refluxed for 2 h. Remaining thionyl chloride was removed in vacuo to 
give 4-methoxybenzoyl chloride. Under Ar gas, a solution of 4-methoxybenzoyl chloride 
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(1.000 g, 5.862 mmol) in 10 mL CH2Cl2 was slowly added to a solution of 
diethylenetriamine (0.588 mL, 5.862 mmol) and 2 mL TEA in 10 mL CH2Cl2 at 0 °C. The 
reaction mixture was stirred for 2 h, and the slurry was diluted with additional CH2Cl2 and 
washed with 1 M NaOH. The organic layer was dried with Na2SO4, and the solvent was 
concentrated under reduced pressure. The residue was purified by silica gel column 
chromatography with CH2Cl2/methanol (5:1, v/v) with 1-2% TEA as the eluent to yield N-(2-
((2-aminoethyl)amino)ethyl)-4-methoxybenzamide. Yield: 20%. 1H NMR (CDCl3): δ 7.79 
(d, 2H), 6.90 (d, 2H), 3.82 (s, 3H), 3.91 (s, 24H), 3.27 (m, 2H), 2.90 (m, 4H), 2.75 (m, 2H). 
N-(2-((2-aminoethyl)amino)ethyl)-4-methoxybenzamide (130 mg, 0.55 mmol) was reacted 
with PEG2K-bis-carboxylate  (1.2 g, 0.55 mmol) in 80 mL anhydrous CH2Cl2 in the presence 
of N,N’-dicyclohexylcarbodiimide (230 mg, 1.1 mmol) and 4-dimethylaminopyridine (135 
mg, 1.1 mmol) under N2 for 48 h. After solvent concentration, 300 mL diethyl ether was 
added to the mixture, and the crude product precipitated out and was isolated by 
centrifugation. The product was purified by silica gel column chromatography with 
CH2Cl2/methanol (10:1 v/v) as the eluent to afford AA-PEG2K-mono-carboxylate. Yield: 
35%.1H NMR (CDCl3): δ 7.77 (m, 2H), 6.89 (d, 2H), 4.20 (m, 2H), 3.95 (s, 3H), 3.81 (t,4H), 
3.61 (s,180H)3.44 (m, 2H). AA-PEG2K-mono-carboxylate (300 mg, 0.13 mmol) was reacted 
with DSPE (115 mg, 0.15 mmol) in 25 mL anhydrous CH2Cl2 in the presence of N,N’-
dicyclohexylcarbodiimide (53 mg, 0.26mmol) and 4-dimethylaminopyridine (31.3 mg, 0.26 
mmol) under N2 for 48 h. After solvent concentration, 50 mL diethyl ether was added to the 
mixture, and the crude product precipitated out and was isolated by centrifugation. The 
product was then purified by silica gel column chromatography with CH2Cl2/methanol (10:1 
v/v) as the eluent to afford AA-PEG2K-DSPE. Yield: 30%.1H NMR (CDCl3): δ 7.78 (m, 2H), 
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6.88 (d, 2H), 4.22 (m, 4H), 3.81 (s, 3H), 3.62 (s, 180H), 2.25 (s, 6H), 1.57 (s, 10H), 1.23 (S, 
30H), 0.85 (t, 6H). 
 3.4.3. Synthesis of PMX- and Folate-Containing NCPs 
Synthesis of Mn-PMX NCP. Particles of Mn-PMX were prepared by a surfactant-
assisted heating method. Two reverse (water in oil) microemulsions were prepared by two 50 
mL round bottom flasks receiving 10 mL 0.3 M 0.5 M 1-hexanol in isooctanes and 365 mg 
CTAB (for 0.1 M CTAB). One flask was given (while stirring) 270 µL 0.1 M (4.7 mg, 0.027 
mmol) aq. MnCl2·4H2O. The other flask was given 270 µL 0.1 M (11.5 mg, 0.027 mmol) aq. 
Na2PMX pH = 7.5. Both reverse microemulsions (W = 15) became clear instantly, were 
combined in a microwave vessel, and microwaved at 80 ºC for 20 min using 400 W, 100% 
power, and a 1 min ramping time. The white product was isolated by centrifugation, 
subsequently washed and centrifuged twice with EtOH, and dispersed in EtOH. Yield: 10.2 
mg (86.6 %).  
  Synthesis of Zr-PMX NCP.  Both ZrCl4 (6.98 mg, 0.0300 mmol) and Na2PMX 
(12.90 mg, 0.0300 mmol) were dissolved in 5.7 mL DMF containing 0.3 mL H2O, and the 
solution was heated in a sealed microwave vessel at 60 °C for 5 min without stirring. The 
product was isolated from the resulting blue dispersion by centrifugation at 13,000 rpm for 
15 min, washed by sonication and centrifugation with H2O then EtOH, and dispersed in 
EtOH.  
 Synthesis of Gd-PMX NCP by Solvothermal Method. Na2PMX was acidified by 
dissolving 100 mg (0.2433 mmol) in 0.5 mL H2O and adding dilute HCl until a precipitate 
formed (PMX). The white precipitate was isolated by centrifugation, washed with Et2O and 
allowed to dry under vacuum for 18 h. This PMX was used in the solvothermal synthesis of 
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Gd-PMX. Both Gd(NO3)3·6H2O (13.7 mg, 0.0300 mmol) and PMX (11.4 mg, 0.0300 mmol) 
were dissolved in 5.5 mL DMF, and the solution was heated in a sealed microwave vessel at 
80 °C for 5 min without stirring. The product was isolated from the resulting brown 
dispersion by centrifugation at 13,000 rpm for 15 min, washed by sonication and 
centrifugation with DMF then EtOH, and dispersed in EtOH.  
Synthesis of Gd-PMX by Surfactant-Templated Procedure. Particles of Gd-PMX 
were prepared by a surfactant-assisted heating method. Two reverse (water in oil) 
microemulsions were prepared by two 25 mL round bottom flasks receiving 10 mL 0.3 M 0.5 
M 1-hexanol in isooctanes and 365 mg CTAB (for 0.1 M CTAB). One flask was given 
(while stirring) 270 µL 0.1 M (11.9 mg, 0.027 mmol) aq. Gd(NO3)3·6H2O. The other flask 
was given 270 µL 0.1 M (10.3 mg, 0.027 mmol) aq. Na2PMX pH = 7.5. Both reverse 
microemulsions (W = 15) became clear instantly, were combined in a microwave vessel, and 
microwaved at 80 ºC for 20 min using 400 W, 100% power, and a 2 min ramping time. The 
white product was isolated by centrifugation, subsequently washed/centrifuged twice with 
EtOH, and dispersed in EtOH. Yield: 6.97 mg (48.0 %).  
 Synthesis of Hf-PMX by Solvothermal Method. HfOCl2·8H2O (9.0 mg, 0.022 
mmol) and Na2PMX (5 mg, 0.0106 mmol) were dissolved in 10 mL DMF, and the solution 
was heated in a sealed microwave vessel at 80 °C for 10 min without stirring. The product 
was isolated from the resulting blue dispersion by centrifugation at 13,000 rpm for 15 min, 
washed by sonication and centrifugation in EtOH, and dispersed in EtOH. 
Synthesis of Hf-PMX by Reverse Microemulsion Method. Particles of Hf-PMX 
were prepared by a reverse microemulsion method. Two reverse (water in oil) 
microemulsions were prepared by two 20 mL glass vials receiving 5 mL 0.3 M TritonX-
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100/1.5 M 1-hexanol in cyclohexane. One flask was given (while stirring) 200 µL 25 mg/mL 
(5 mg, 0.0122 mmol) aq. HfOCl2·8H2O. The other flask was given 200 µL 25 mg/mL (5 mg, 
0.0106 mmol) aq. Na2PMX pH = 7.5. Both reverse microemulsions (W = 7.4) became clear 
instantly, were combined and stirred for 1 h. 15 µL 200 mg/mL (3 mg, 0.00414 mmol) 
DOPA in CHCl3 was added, and the reverse microemulsion was stirred for another hour; the 
reaction was quenched with the addition of 10 mL EtOH and stirred for 1 h. The white 
product was isolated by centrifugation, subsequently washed/centrifuged once with 
cyclohexane and twice with THF, and dispersed in THF. Yield: 1.86 mg (30.0 %).  
Synthesis of Hf-Folate NCP. HfOCl2·8H2O (20.4 mg, 0.0498 mmol) and folic acid 
(22.2 mg, 0.0503 mmol) were dissolved in 10 mL DMF, followed by the addition of 400 µL 
0.1 M (0.04 mmol) H3PO4 aq. The solution was heated in a sealed microwave vessel at 80 °C 
for 5 min without stirring. The product was isolated from the resulting orange dispersion by 
centrifugation at 13,000 rpm for 15 min, washed by sonication and centrifugation twice with 
EtOH, and dispersed in EtOH. Yield: 22.3 mg (72.0 %). 
Synthesis of DOPA-Capped Hf-Folate NCP. Hf-folate NCPs (10 mg) were isolated 
by centrifugation and dispersed in a 1:7 v/v EtOH/CHCl3 solution. While stirring, 75 µL 200 
mg/mL (15 mg, 0.0207 mmol) DOPA in CHCl3 was added, and the dispersion was stirred at 
room temperature for 2 h. Particles were isolated by centrifugation, washed by sonication and 
centrifugation with THF, and dispersed in THF.  
 3.4.4. Lipid Coating Procedure 
 Lipid Coating of Gd-PMX with 1:1 DSTAP/DOPE. Particle dispersions of Gd-
PMX and various amounts of 1:1 (by mol) DSTAP/DOPE  liposomes in 1 mM aq. KCl were 
combined and the sample was vortexed and sonicated then analyzed by DLS in 1 mM KCl. 
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Lipid Coating of Hf-PMX with cholesterol/DOPC/DSPE-Peg2K. Particles of Hf-
PMX (0.5 mg) were isolated by centrifugation and dispersed in 100 µL THF. All lipid 
solutions (5 mg/mL in THF) and the particle dispersion were heated to 50 ºC in a water bath. 
The following lipids were added to the particle dispersion: 42 µL (0.21 mg, 0.543 µmol) 
cholesterol, 84 µL (0.42 mg, 0.543 µmol) DOPC, and 150 µL (0.75 mg, 0.273 µmol, 20 
mol%) DSPE-Peg2K. A solution of EtOH/H2O (30 % v/v, 500 µL) was heated to 50 ºC, and, 
while stirring at the maximum rate, the particle dispersion was added dropwise. THF was 
removed by an N2 stream.  
Lipid Coating and Anisamide Targeting of Hf-PMX. Particles of Hf-PMX (0.5 
mg) were isolated by centrifugation and dispersed in 100 µL THF. All lipid solutions (5 
mg/mL in THF) and the particle dispersion were heated to 50 ºC in a water bath. The 
following lipids were added to the particle dispersion: 42 µL (0.21 mg, 0.543 µmol) 
cholesterol, 84 µL (0.42 mg, 0.543 µmol) DOPC, 135 µL (0.675 mg, 0.245 µmol) DSPE-
Peg2K, and 15 µL (0.075 mg, 0.025 µmol) DSPE-Peg2K-AA. A solution of EtOH/H2O (30 % 
v/v, 500 µL) was heated to 50 ºC, and, while stirring, the particle dispersion was added 
dropwise. THF was removed by an N2 stream.  
Lipid Coating of Hf-Folate. Particles of Hf-Folate (0.7 mg) were isolated by 
centrifugation and dispersed in 100 µL THF. All lipid solutions (5 mg/mL in THF) and the 
particle dispersion were heated to 50 ºC in a water bath. The following lipids were added to 
the particle dispersion: 42 µL (0.21 mg, 0.543 µmol) cholesterol, 84 µL (0.42 mg, 0.543 
µmol) DOPC, and 150 µL (0.75 mg, 0.273 µmol, 20 mol%) DSPE-Peg2K. A solution of 
EtOH/H2O (30 % v/v, 500 µL) was heated to 50 ºC, and, while stirring, the particle 
dispersion was added dropwise. THF was removed by an N2 stream.  
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Lipid Coating and Anisamide-Targeting of Hf-Folate. Particles of Hf-Folate (0.7 
mg) were isolated by centrifugation and dispersed in 100 µL THF. All lipid solutions (5 
mg/mL in THF) and the particle dispersion were heated to 50 ºC in a water bath. The 
following lipids were added to the particle dispersion: 42 µL (0.21 mg, 0.543 µmol) 
cholesterol, 84 µL (0.42 mg, 0.543 µmol) DOPC, 135 µL (0.675 mg, 0.245 µmol) DSPE-
Peg2K, and 15 µL (0.075 mg, 0.025 µmol) DSPE-Peg2K-AA. A solution of EtOH/H2O (30 % 
v/v, 500 µL) was heated to 50 ºC, and, while stirring, the particle dispersion was added 
dropwise. THF was removed by an N2 stream.  
Release Profiles. All release profiles were carried out in 5 mM PBS at 37 ºC. A 1 L 
solution of 5 mM PBS was prepared by dissolving 8.528 g (0.146 mol) NaCl and 680 mg (5 
mmol) KH2PO4 in 500 mL MilliQ H2O. The pH was adjusted to 7.4 with NaOH, and the 
solution was brought to 1 L with MilliQ H2O. Between 2-4 mg PMX-containing NCPs were 
prepared in 500 µL PBS or 30 % v/v EtOH/H2O and added to a length of 10K molecular 
weight cutoff dialysis tubing. The dialysis tubing was submerged in a beaker containing 400 
mL 5 mM PBS stirring at 37 ºC. Aliquots of 1 mL each were removed from the beaker at 
designated time intervals, and the volumes were replaced with fresh PBS. Samples were 
digested in 0.5 mL 0.3 M H3PO4, filtered through a 0.2 µM PTFE syringe filter, and analyzed 
by UV-Vis for PMX content. PMX content (in µM) was converted to % drug released. 
 DLS Stability Assays in PBS with Bovine Serum Album (BSA). Lipid-coated Hf-
PMX was prepared in 500 µL 30% v/v EtOH/H2O and added to 500 µL 5 mM PBS. BSA (5 
mg) was dissolved in the particle dispersion, and Z average diameter, PDI, and count rate 
were monitored for 18 h. 
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  Lipid Coating and AA Targeting of Hf-PMX. These lipid-coated particles were 
produced by the same technique as the non-targeted formulation, but using the same amount 
of cholesterol and DOPC, 135 µL 5 mg/mL (0.675 mg, 2.45 x 10-4 mmol) DSPE-Peg2K and 
15 µL 5 mg/mL (0.075 mg, 2.5 x 10-5 mmol) DSPE-Peg2K-AA in THF. 
  3.4.5. In Vitro Assay Methods 
Cell Lines. NCI-H460 non-small cell lung cancer cells (ATCC# HTB-177) and A549 
non-small cell lung cancer cells (ATCC# CCL-185) were purchased from the Tissue Culture 
Facility of Lineberger Comprehensive Cancer Center at the University of North Carolina at 
Chapel Hill. Both cell lines were maintained in RPMI-1640 growth medium supplemented 
with 10% FBS and 2% penicillin-streptomycin. 
 Cytotoxicity Assays Against A549 NSCLC Cells. For the Gd-PMX Assay: 
Confluent A549 cells were trypsinized and a cell density was obtained from a 
hemocytometer. Six-well plates were seeded with 5.0x104 cells/well and a total of 2 mL 
media. Plates were incubated at 37°C and 5% CO2 overnight. Amounts of PMX or NCP 
suspension in RPMI-1640 medium were added to wells, along with additional media, 
resulting in PMX concentrations (µM) of 0, 1, 5, 10, 50, and 100. Plates were incubated at 
37°C and 5% CO2 for 48 h and viability was determined via the trypan blue exclusion assay. 
 For the Hf-PMX Assay: Confluent A549 cells were trypsinized and a cell density was 
obtained from a hemocytometer. Six-well plates were seeded with 5.0x104 cells/well and a 
total of 2 mL media. Plates were incubated at 37°C and 5% CO2 overnight. Amounts of PMX 
or Hf-PMX dispersions in RPMI-1640 medium were added to wells, along with additional 
media, resulting in PMX concentrations (µM) of 0, 0.15, 0.5, 0.75, 1, and 2. Plates were 
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incubated at 37°C and 5% CO2 for 48 h and viability was determined via the trypan blue 
exclusion assay. 
 Cytotoxicity Assay Against NCI-H460 NSCLC Cells. Confluent NCI-H460 cells 
were trypsinized and a cell density was obtained from a hemocytometer. Six-well plates were 
seeded with 5.0x104 cells/well and a total of 2 mL media. Plates were incubated at 37°C and 
5% CO2 overnight. Amounts of PMX or Hf-PMX dispersions in RPMI-1640 medium were 
added to wells, along with additional media, resulting in PMX concentrations (µM) of 0, 
0.15, 0.5, 0.75, 1, and 2. Plates were incubated at 37°C and 5% CO2 for 48 h and viability 
was determined via the trypan blue exclusion assay. 
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CHAPTER 4 
 
Nanoscale Coorination Polymers for Targeted Delivery of Cisplatin 
 
 
4.1. Introduction 
 
4.1.1. Platinum Complexes for Cancer Chemotherapy - Cisplatin 
 
Cancer treatment was revolutionized by the serendipitous discovery of the biological 
properties of cisplatin in 1965 by Rosenberg and co-workers.1 Since this discovery, there 
have been three FDA-approved Pt-based anticancer agents: cisplatin, oxaliplatin, and 
carboplatin. This chapter will focus on the delivery of cisplatin (Figure 4.1); NCPs for the 
delivery of oxaliplatin will be discussed in Chapter 5. These drugs, as with all small molecule 
chemotherapeutics, are used to treat various cancers, are vastly limited by their poor 
pharmacokinetics, low selectivity, and detrimental side effects. These agents, with their short 
half-lives in the body, diffuse through all tissues, resulting in high systemic toxicity.2-4 
Nephrotoxicity and neurotoxicity are not uncommon for patients treated specifically with Pt-
based therapeutics.  
 
Figure 4.1. Structure of cisplatin, one of the three FDA-approved platin-based 
chemotherapeutics. 
 
Cisplatin has a defined mechanism of action against cancer (Figure 4.2).5,6 Upon 
entry into a cell, cisplatin becomes aquated by loss of the two chloro ligands, as a result of 
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the lower chloride concentration inside the cell (3-20 mM) than outside of the cell (~100 
mM). The resulting diaquo cisplatin (or the mono-aquated form) is the active drug, which 
forms adducts with the strands of DNA, inhibiting repair and replication. These adducts bend 
and twist DNA, triggering many signal-transduction pathways that ultimately result in 
apoptosis. 
 
Figure 4.2. Mechanism of cisplatin in apoptotic cell death. 
 
This mechanism of action seems rather straightforward and effective; however, many 
cancers develop resistance to cisplatin.2 Resistance, as well as other drawbacks of cisplatin 
therapy, can be much alleviated by the incorporation of a cisplatin prodrug into an NCP. 
Other nanoparticle carriers have been utilized for the delivery of cisplatin,7-10 but the Lin 
group is the only group to use an NCP platform for delivery of this chemotherapeutic. 
Although an earlier silica-coated NCP formulation was developed in the Lin lab to deliver 
cisplatin at very high drug loadings, this system suffers from the burst release of significant 
amounts of drug from the particles.11 Herein is reported the synthesis and characterization of 
new cisplatin-containing NCPs which have been stabilized by lipid coatings and 
functionalized with the small molecule targeting ligand, anisamide (AA), which displays an 
106 
 
affinity for sigma receptors (Figure 4.3). The present NCP system shows enhanced efficacy 
compared to cisplatin in non-small cell lung cancer (NSCLC) cell lines; increased uptake is 
further demonstrated by confocal microscopy imaging and competitive binding assays. 
 
Figure 4.3. Schematic showing the synthesis of La-DSCP NCPs, stabilization with a lipid 
bilayer, and uptake into lung cancer cells. 
 
 
4.2. Results and Discussion 
 4.2.1. Synthesis and Characterization of Mg-DSCP NCP 
 
 NCPs of Mg-DSCP were prepared by a nanoprecipitation technique in which the 
methylammonium salt of disucccinatocisplatin (DSCP) and MgCl2·6H2O were dissolved in 
H2O and the formation of NCPs was induced by the rapid addition of MeOH. These particles 
are slightly fused and between 100-150 nm in diameter by SEM (Figure 4.4). However, these 
particles were not stable and degraded shortly after their storage in EtOH. 
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Figure 4.4. SEM micrograph of Mg-DSCP NCPs. 
 
 4.2.2. Synthesis and Characterization of Mn-DSCP NCP 
 Two formulations of Mn-DSCP NCPs were prepared. First, NCPs were synthesized 
by a nanoprecipitation technique in which the methylammonium salt of DSCP and 
MnCl2·4H2O were dissolved in H2O and the formation of NCPs was induced by the rapid 
addition of MeOH. These particles are slightly fused and between 100-200 nm in diameter by 
SEM (Figure 4.5). The particles possess a moderate DSCP loading, 31.8 wt% by TGA 
(Figure 4.6). The ICP-MS analysis for Pt content yields 10.6 wt% Pt which translates to ~30 
wt% DSCP, a drug loading that agrees well with the TGA data. These particles were slightly 
fused, which hindered their further development as a drug delivery vehicle. 
 Another version of Mn-DSCP NCPs were prepared by a surfactant-assisted heating 
method in which reverse microemulsions (W = 10) containing aqueous phase 
methylammonium DSCP salt and MnCl2·4H2O were stabilized in the organic phase 0.1 M 
CTAB/0.5 M 1-hexanol in isoocatnes and heated to 120 °C for 10 min. The resulting 
spherical particles were between 50-200 nm in diameter by SEM (Figure 4.7). However, the 
inability to reproduce this synthesis precluded its use in further studies. 
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Figure 4.5. SEM micrograph of Mn-DSCP NCPs.  
 
 
 
Figure 4.6. TGA plot of Mn-DSCP showing organic weight loss corresponding to 31.8 wt% 
DSCP drug loading. DSCP organic weight loss is observed between 150 and 275 °C. 
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Figure 4.7. SEM micrograph of Mn-DSCP synthesized by a surfactant-assisted heating 
synthesis. 
 
4.2.3. Synthesis and Characterization of Zr-DSCP NCP 
 
We sought to synthesize NCPs of Zr-DSCP because a Zr-carboxylate MOF was 
reported to have high stability12 (note: this work was done concurrently with MTX-
containing NCPs (Chapter 2) so conclusions about the stability of Zr-based NCPs had not 
been made). The first generation of Zr-DSCP was made by a solvothermal method in which 
ZrCl4, DSCP, and 5 eq. acetic acid were combined in DMF and heated in an oven at 60 °C 
for 18 h. The resulting amorphous NCPs were ~400 nm in diameter by both SEM and TEM 
(Figure 4.8). This size correlates well with the Z average diameter of 432.1 nm and PDI of 
0.106 by DLS. These nanoparticles display a high drug loading of DSCP, 41.1 wt% by TGA 
(Figure 4.9). These larger Zr-DSCP NCPs are too large for drug delivery applications, so 
attempts were made to produce smaller (less than 200 nm diameter) Zr-DSCP particles. 
Smaller Zr-DSCP particles were prepared by a solvothermal reaction in which ZrCl4, DSCP, 
and acetic acid were heated in a microwave in DMF at 60 °C for 5 min. The resulting white 
particles were ~50 nm and slightly fused by SEM (Figure 4.10). The fused particles are 
evident from DLS, with a Z average diameter of 204.9 nm and PDI of 0.194 in EtOH. 
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Particles of Zr-DSCP that were not fused were prepared by the acetone-induced nano-
precipitation of a solution of ZrCl4, DSCP, and 5 eq. acetic acid in DMF. Smaller particles 
were achieved by the acetone-induced nanoprecipitation of a solution of ZrCl4, DSCP, and 
acetic acid in DMF. The particles resulting from this reaction were between 100-200 nm in 
diameter by SEM and TEM (Figure 4.11) with a Z average diameter of 190.0 nm with a PDI 
of 0.080 by DLS. TGA gives a DSCP drug loading of 27.1 wt% (Figure 4.12). This drug 
loading value matches that obtained by ICP-MS analysis of Pt content, 28.1 wt%. These 
particles dissolve instantly in 5 mM PBS at 37 °C with a t1/2 ~ 10 min, indicating the need for 
further stabilization (Figure 4.13).  
 
  
Figure 4.8. SEM (a) and TEM (b) micrographs of larger Zr-DSCP. 
a) b) 
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Figure 4.9. TGA plot of larger Zr-DSCP NCPs showing organic weight loss corresponding 
to 41.1 wt% DSCP between 150 and 300 °C. 
 
 
 
Figure 4.10. SEM micrograph of Zr-DSCP NCPs synthesized by solvothermal synthesis. 
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Figure 4.11. SEM micrograph of Zr-DSCP NCPs by acetone-induced rapid precipitation. 
 
Figure 4.12. TGA plot of Zr-DSCP where organic weight loss corresponds to 27.1 wt% 
DSCP between 150 and 300 °C. 
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Figure 4.13. Release profile of Zr-DSCP in 8 mM PBS at 37 °C. 
 
Additionally, a Zr-DSCP NCP formulation in which the particles are capped with a 
hydrophobic capping agent (DOPA) was made to perhaps have these particles stabilized by a 
different lipid coating method.13 These particles were made by the chloroform-induced nano-
precipitation of a solution of ZrCl4, DSCP, DOPA, and acetic acid in DMF. These particles, 
called Zr-DSCP@DOPA, are between 100-200 nm in diameter by SEM and TEM (Figure 
4.14). The size in THF by DLS is a Z average diameter of 224.8 nm with a PDI of 0.116. 
TGA of this material shows more organic weight loss than the uncapped Zr-DSCP, indicating 
the addition of the DOPA capping agent (Figure 4.15). ICP-MS of Pt content gives 32.9 wt% 
DSCP. A release profile of these particles in 5 mM PBS at 37 °C gives a t1/2 ~30 min (Figure 
4.16). Attempts to stabilize this material by lipid coating are described in a later section. 
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Figure 4.14. SEM (a) and TEM (b) micrographs of DOPA-capped Zr-DSCP. 
 
Figure 4.15. TGA plot of DOPA-capped Zr-DSCP, showing more organic weight loss (due 
to the addition of DOPA) than Zr-DSCP. 
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Figure 4.16. Release profile of Zr-DSCP@DOPA in 8 mM PBS at 37 °C. 
 
4.2.4. Stabilization Attempts of Zr-DSCP NCP 
It has been previously reported that NCPs can be stabilized by the subsequent coating 
with polyvinylpyrollidone (PVP) and silica.11 Zr-DSCP NCPs were coated with PVP by 
stirring a dispersion of Zr-DSCP in EtOH containing PVP for 18 h. Coating the particles with 
PVP before silica coating make the particles more dispersible so that more efficient silica 
coating can be achieved. The resulting particles do not differ in size from the as-synthesized 
particles, but appear more dispersible on the SEM or TEM slide (Figure 4.17). These 
particles appear smaller by DLS with a Z average diameter of 158.3 nm and a PDI of 0.155, 
indicating that the particles are more dispersible in EtOH. An increase in organic weight loss 
between Zr-DSCP and Zr-DSCP@PVP by TGA indicates the added amount of PVP, 12.0 
wt% (Figure 4.18). After successful coating of Zr-DSCP with PVP, the particles were coated 
with silica to afford Zr-DSCP@PVP@SiO2. Silica coating was achieved by stirring Zr-
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DSCP@PVP in a basic ethanol solution containing tetraethyl orthosilicate for 2 h. The 
resulting particles do not differ in size from the as-synthesized particles by SEM or TEM 
(Figure 4.19). 
  
Figure 4.17. SEM (a) and TEM (b) micrographs of Zr-DSCP@PVP. 
 
Figure 4.18. TGA plot of Zr-DSCP@PVP, compared to Zr-DSCP, showing increased 
organic weight loss due to the presence of DOPA. DSCP weight loss is observed between 
175 and 350 °C. 
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Figure 4.19. SEM (a) and TEM (b) micrographs of Zr-DSCP@PVP@SiO2. 
 
Zr-DSCP@PVP@SiO2 NCPs increase in size from the PVP-coated NCPs by DLS 
with a Z average diameter of 209.3 nm and PDI of 0.123. EDS shows the presence of Pt, Zr, 
and Si, which indicates successful silica coating (Figure 4.20); however, ICP-MS analysis of 
Pt gives the same DSCP drug loading as the as-synthesized particles, 32.9 wt%. TGA shows 
that the weight loss characteristics are the same for Zr-DSCP and the silica-coated particles, 
indicating that all PVP may have been lost and the amount of silica coating is minimal. 
Unfortunately, silica coating of Zr-DSCP@PVP did not enhance stability of the NCPs. 
a) b) 
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Figure 4.20. EDS plot of Zr-DSCP@PVP@SiO2 showing the presence of Zr, Pt, and Si.  
 
 We also attempted to induce stability by lipid-coating Zr-DSCP@DOPA by injecting 
a dispersion of particles and cholesterol, DOPC, and DSPE-Peg2K in THF into 30 % v/v 
EtOH/H2O and removing the THF by a N2 stream. These particles do not differ from the as-
synthesized particles by TEM (Figure 4.21) or DLS (Z average diameter = 200.0 nm, PDI = 
0.141). Unfortunately, these lipid-coated Zr-DSCP@DOPA NCPs did not lead to any 
stabilization by a release profile in 5 mM PBS at 37 °C (t1/2 ~ 25 min). The inability to 
stabilize any of the Zr-DSCP NCPs is likely due to the tendency of Zr-carboxylate materials 
to rapidly form phosphate salts in the presence of phosphates, as demonstrated in the case of 
Zr-MTX.14 
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Figure 4.21. TEM micrograph of lipid-coated Zr-DSCP@DOPA NCPs. 
  
4.2.5. Synthesis and Characterization of La-DSCP NCP 
 
Knowing that trivalent lanthanides have a reduced tendency to form phosphate salts, 
we sought to prepare a DSCP-containing NCP with La(III) as the binding metal. This system 
differs from that of the previously reported Tb-DSCP material as we had hoped that lipid-
coating a hydrophobic NCP would lead to less burst release and an overall more stable 
formulation. DOPA-capped NCPs of La-DSCP were produced by a surfactant-assisted 
heating technique in which reverse microemulsions (W = 7.4) containing aqueous droplets of 
LaCl3·7H2O and DSCP (containing DOPA in CHCl3) in the organic phase 0.3 M TritonX-
100/1.5 M 1-hexanol in cyclohexane were heated at 70 °C for 10 min. The resulting NCPs 
were irregularly-shaped and between 50-150 nm by SEM and TEM (Figure 4.22). DLS 
analysis in THF shows that the particles are dispersible in organic solvent (Z average 
diameter = 133.0 nm, PDI = 0.120), indicating successful capping with the hydrophobic 
capping agent. 
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Figure 4.22. SEM (a) and TEM (b) micrographs of La-DSCP NCP. 
 
 ICP-MS analysis for Pt content reveals that these particles are 8.2 wt% DSCP (20 
wt% La). Even though this drug loading is considered low for NCP formulations, cisplatin is 
a very potent chemotherapeutic agent and when delivered selectively and specifically to 
cancer tissue, the dose required is quite low. TGA shows a large amount of organic weight, 
presumably due to a significant amount of DOPA associated with the formulation (Figure 
4.23). A release profile in 5 mM PBS at 37 °C shows that the formulation degrades almost 
immediately (Figure 4.24, t1/2 ~ 35 min), emphasizing the requirement to stabilize this 
material. 
 
a) b) 
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Figure 4.23. TGA plot of La-DSCP showing a large amount of organic weight loss attributed 
mostly to the presence of DOPA. 
 
 
Figure 4.24. Release profile of La-DSCP in 8 mM PBS at 37 °C. 
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4.2.6. Lipid Coating of La-DSCP NCP 
 La-DSCP NCPs were stabilized by addition of a lipid coating by encapsulation in a 
lipid layer of cholesterol, DOPC, and DSPE-Peg2K in a 2:2:1 molar ratio following a reported 
protocol.13 A dispersion of La-DSCP and lipids in THF was added dropwise to a solution of 
30 % v/v EtOH/H2O stirring at 50 °C. These particles are not any different in morphology 
from the as-synthesized particles by TEM (Figure 4.25). An increase in Z average diameter 
(163.0 nm with a PDI of 0.140) is observed by DLS in PBS. Increased stability is observed 
compared to the as-synthesized La-DSCP NCPs in a release profile in 5 mM PBS at 37 °C 
(Figure 4.26). Over the first hour, ~25% drug release is observed, with no more Pt release 
observed by ICP-MS up to 192 h. This type of release profile is desired as the remaining 
DSCP loading would be released inside the cell environment via the pH-labile Pt-O bonds in 
the Pt(IV) prodrug. This enhanced stability is quite an improvement from the previously 
reported Tb-DSCP system (t1/2 ~ 9 h with complete release at 42 h).11  
 
Figure 4.25. TEM micrograph of La-DSCP@Lipid. 
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Figure 4.26. Release profile of La-DSCP@Lipid in 8 mM PBS at 37 °C, showing enhanced 
stability over the as-synthesized NCPs. 
 
 
Further stability tests were conducted on the lipid-coated La-DSCP NCPs. First, the Z 
average diameter was monitored in 5 mM PBS for 18 h to show that the diameter remains the 
same over this time period (Figure 4.27a). Additionally, this same experiment was conducted 
in 5 mM PBS containing 5 mg/mL bovine serum albumin (Figure 4.27b, BSA). BSA is a 
blood protein that is used to assess the potential stability of the NCP formulation in blood 
circulation. Poorly PEGylated particles would aggregate significantly in the presence of BSA 
as PEG creates a water layer that impedes blood proteins from attaching to the material. 
When the particle diameter is monitored over 18 h in 5 mg/mL BSA, no aggregation is 
observed (the PDI remains the same) and a ~20 nm decrease in Z average is observed, likely 
due to the settling out of larger particles overnight. 
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Figure 4.27. (a) DLS stability of La-DSCP@DOPA@Lipid in PBS overnight. The Z average 
diameter slowly stabilizes to 130 nm, which may indicate a small population of larger 
particles settles out. Zavg = 139.2 ± 9.3 nm, PDI = 0.153 ± 0.013, and count rate = 330.4 ± 
27.3 kcps. (b) DLS stability of La-DSCP@DOPA@Lipid in 5 mM PBS with 5 mg/mL BSA. 
Zavg = 146.5 ± 5.1 nm, PDI = 0.238 ± 0.010, and count rate = 325.1 ± 16.2 kcps. 
 
 
100
120
140
160
180
200
4890 4900 4910 4920 4930 4940 4950 4960 4970
Z-
Av
er
ag
e 
(d
.n
m
)
Record Number
Z-Average Trend
Z-Average Polydispersity in nanometres
100
120
140
160
180
200
5020 5030 5040 5050 5060 5070 5080 5090 5100
Z-
Av
er
ag
e 
(d
.n
m
)
Record Number
Z-Average Trend
Z-Average Polydispersity in nanometres
a) 
b) 
125 
 
The lipid-coated La-DSCP NCPs were modified with DSPE-Peg2K-AA to be rendered 
cancer specific as AA is known to target sigma receptors that are overexpressed on epithelial 
cancer tissues.15-20 AA-modified NCPs were prepared by replacing DSPE-Peg2K with both 
DSPE-Peg2K and DSPE-Peg2K-AA in a 9:1 molar ratio during the lipid coating procedure. 
These particles are the same size and morphology as the non-targeted formulation and 
display similar DLS stability characteristics in an abbreviated BSA assay (Figure 4.28). 
 
Figure 4.28. DLS stability of La-DSCP@DOPA@Lipid-AA in 5 mM PBS with 5 mg/mL 
BSA over 1 h. 
 
 
4.2.7. Synthesis and Characterization of La-Suc NCP 
 
Control vehicles, La(III) NCP formulations that do not contain the cisplatin prodrug, 
were prepared for in vitro viability assays. Succinic acid (Suc) was used as the ligand instead 
of the cytotoxic prodrug, and particles of La-Suc were prepared by a similar surfactant-
templated heating method as the La-DSCP NCP. Lipid-coated and AA-targeted versions of 
these control vehicles were prepared using the same lipid coating strategies described above 
for La-DSCP. Particles of La-Suc were the same size and morphology as the La-DSCP NCPs 
by both SEM and TEM (Figure 4.29). La-Suc has a Z average diameter similar to La-DSCP 
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as well (141.0 nm with a PDI of 0.137). The Z average diameters for the lipid-coated non-
targeted and targeted La-Suc NCPs are 227.6 nm (PDI of 0.211) and 185.6 nm (PDI of 
0.282), respectively. These formulations were used in in vitro viability assays with NSCLC 
cell lines. 
  
Figure 4.29. SEM (a) and TEM (b) micrographs of La-Suc control vehicle NCPs. 
 
4.2.8. In Vitro Cytotoxicity and Viability Assays 
 
Larger Zr-DSCP NCPs were tested in a 72 h in vitro cytotoxicity assay against NCI-
H460 NSCLC cells (Figure 4.30). Compared to free cisplatin, both cisplatin and Zr-DSCP 
have the same IC50 value of ~ 1 µM. This is expected because as-synthesized Zr-DSCP will 
degrade in the cell medium and will essentially become the equivalent of free cisplatin. La-
DSCP formulations were tested in a 48 h trypan blue exclusion assay against NCI-H460 cells 
(Figure 4.31). NCI-H460 cells are known to overexpress sigma receptors. IC50 values (µM) 
were: cisplatin = 0.53 ± 0.14, La-DSCP = 5.57 ± 0.40, La-DSCP@Lipid = 0.67 ± 0.06, and 
La-DSCP@Lipid-AA = 0.32 ± 0.03. There is a statistically significant difference between the 
IC50 values for the non-targeted and AA-targeted NCPs by the t test (α ≤ 0.05). Thus, it can 
be concluded that targeting with AA leads to a significant improvement in efficacy. 
a) b) 
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Figure 4.30. In vitro cytotoxicity curves for cisplatin and large Zr-DSCP against NCI-H460 
NSCLC cells over 72 h. 
 
 
Figure 4.31. In vitro cytotoxicity curves for cisplatin and La-DSCP formulations against 
NCI-H460 cells for 48 h. 
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The La-DSCP formulations were also tested for efficacy in the A549 NSCLC cell 
line, a cell line that has very minimal expression of sigma receptors. For a 48 h trypan blue 
exclusion assay, IC50 values (µM) were: cisplatin = 2.20 ± 0.17, La-DSCP = 5.90 ± 1.03, La-
DSCP@Lipid = 1.20 ± 0.53, and La-DSCP@Lipid-AA = 1.33 ± 0.32 (Figure 4.32). There 
was not a statistically significant difference between IC50 values of the non-targeted and AA-
targeted La-DSCP formulations by the t test (α = 0.32), likely due to lack of expression of 
sigma receptors for this cell line. 
 
Figure 4.32. In vitro cytotoxicity assay testing cisplatin and La-DSCP formulations against 
A549 NSCLC cells for 48 h. 
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from La(III) or the lipid coating formulation. Additionally, a viability test was done to test 
from LaCl3 salt to observe any cytotoxic effects from the amount of La(III) that would be 
released from La-DSCP during the assay. This amount was determined by the ICP-MS 
analysis for La content (La-DSCP = 20 wt% La). No cytotoxic effects were observed for 
NCI-H460 cells (Figure 4.35) or A549 cells (Figure 4.36). 
 
Figure 4.33. In vitro viability assay testing La-Suc formulations against NCI-H460 NSCLC 
cells for 48 h, showing no cytotoxic effects. 
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Figure 4.34. In vitro viability assay testing La-Suc formulations against A549 NSCLC cells 
for 48 h, showing no cytotoxic effects. 
 
 
Figure 4.35. In vitro viability assay testing LaCl3 salt against NCI-H460 NSCLC cells for 48 
h, showing no cytotoxic effects. 
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Figure 4.36. In vitro viability assay testing LaCl3 salt against A549 NSCLC cells for 48 h, 
showing no cytotoxic effects. 
 
 
4.2.9. Synthesis and Characterization of Ru(bpy)32+-Containing NCPs 
 
La-Suc NCPs doped with the optical imaging agent Ru(bpy)32+ were prepared by a 
similar surfactant-templated heating method in which ~10 mol% [Ru(5,5’-CO2H-
bpy)(bpy)2](PF6)2 was added to the reverse microemulsion containing Suc. These particles 
were used in laser scanning confocal microscopy studies. Particles are between 50-200 nm by 
SEM and TEM (Figure 4.37) and have a Z average diameter of 187.3 nm with a PDI of 
0.238. Like their non-doped counterparts, these particles possess a large amount of organic 
weight by TGA (Figure 4.38), presumably due to the large amount of DOPA associated with 
these particles. The presence of Ru was confirmed by ICP-MS (0.5 wt%). The presence of 
Ru(bpy)32+ in these doped La-Suc NCPs was also confirmed by fluorescence spectroscopy 
(Figure 4.39). A broad emission characteristic of Ru(bpy)32+ is observed at ~ 620 nm. 
0
20
40
60
80
100
0 0.5 1 2.5 5 10
V
ia
bi
lit
y 
%
Equivalent [Pt], µM
132 
 
 
  
Figure 4.37. SEM (a) and TEM (b) micrographs of Ru(bpy)32+-doped La-Suc NCPs. 
 
Figure 4.38. TGA plot of Ru(bpy)32+-doped La-DSCP showing a large amount of organic 
weight loss, presumably due to DOPA associated with the particles. 
 
 
0
20
40
60
80
100
0 200 400 600
W
ei
gh
t %
Temperature (°C)
a) b) 
133 
 
 
Figure 4.39. Florescence spectra of  La-DSCP and Ru(bpy)32+-doped La-DSCP, showing 
emission of Ru(bpy)32+ at ~620 nm (excitation 450 nm). 
 
4.2.10. Confocal Microscopy 
 
Enhanced uptake of the AA-targeted La-DSCP formulation was confirmed by laser 
scanning confocal microscopy. Particles of Ru(bpy)32+-doped La-Suc were incubated with 
NCI-H460 cells for 30 min and imaged on a confocal microscope (Figure 4.40). Images show 
almost no fluorescence for La-Suc, likely due to rapid degradation of the as-synthesized 
particles. Slightly more fluorescence is observed for La-Suc@Lipid, but intense fluorescence 
from La-Suc@Lipid-AA is observed, indicating enhanced uptake due to active targeting of 
these targeted particles.   
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Figure 4.40. Laser scanning confocal microscopy images showing DIC (b, d, f, h) and red 
fluorescence (a, c, e, g) attributed to particle fluorescence from Ru(bpy)32+: (a, b) control (no 
particles), (c, d) La-Suc, (e, f) La-Suc@Lipid, and (g, h) La-Suc@Lipid-AA. Scale bars = 20 
μm. 
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4.2.11. Competitive Binding Assays 
 
In order to further confirm enhanced uptake due to active targeting of the AA-
targeted La-Suc formulation, competitive binding assays were conducted in which the sigma 
receptors of NCI-H460 cells were saturated with NH3-Peg5K-AA, then incubated with either 
La-DSCP@Lipid or La-DSCP@Lipid-AA. The amount of La and Pt internalized by the cells 
was determined by ICP-MS. As shown in Figures 4.41 and 4.42, the uptakes of both 
formulations are the same when the cells have been incubated with an equal amount of NH3-
Peg5K-AA, which means that the active targeting ability of La-DSCP@Lipid-AA has been 
silenced. Additionally, less uptake of the AA-targeted formulation is observed when the 
amount of NH3-Peg5K-AA is increased.  
 
Figure 4.41. Competitive binding assay showing amount of Pt uptake in NCI-H460 cells 
treated subsequently with amounts of NH2-PEG5K-AA and either La-DSCP@Lipid or La-
DSCP@Lipid-AA. 
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Figure 4.42. Competitive binding assay showing amount of La uptake in NCI-H460 cells 
treated subsequently with amounts of NH2-PEG5K-AA and either La-DSCP@Lipid or La-
DSCP@Lipid-AA. 
 
 
4.3. Conclusion 
In summary, several NCP formulations containing the cisplatin prodrug DSCP were 
prepared using different binding metals; however only one of these formulations could be 
stabilized with encapsulation with a lipid bilayer, La-DSCP. Coating with a 
cholesterol/DOPC/DSPE-Peg2K lipid layer doped with DSPE-Peg2K-AA rendered this 
formulation an active targeting agent for sigma receptors. The resulting formulation proved 
more potent than free cisplatin in NSCLC cell lines; enhanced uptake was demonstrated by 
both confocal microscopy and competitive binding assays. 
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4.4. Experimental Details 
 
4.4.1. Materials and Methods 
 
All chemicals, unless otherwise noted, were purchased from Fisher Scientific or 
Sigma Aldrich and used without further purification. Cisplatin (for synthesis of 
disuccinatocisplatin, DSCP) was purchased from AK Scientific. DSCP was prepared by an 
established procedure.11 1,2-dioleoyl-sn-glycero-3-phosphate (DOPA), 1,2-dioleoyl-sn-
glycero-3-phosphocholine (DOPC), and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
N-(polyethylene glycol) (DSPE-Peg2K) were purchased from Avanti Polar Lipids. Cell 
culturing supplies, fetal bovine serum (FBS), RPMI-1640 growth medium, phosphate 
buffered saline (PBS), penicillin-streptomycin, and trypsin-EDTA were purchased from 
Fisher Scientific. Microwave reactions were carried out in a CEM MARS 5 digestion 
microwave system. Scanning electron microscopy (SEM) was obtained on a Hitachi 4700 
Field Emission Scanning Electron Microscope, and transmission electron microscopy (TEM) 
was obtained on a JEM 100CX-II Transmission Electron Microscope. A Cressington 108 
Auto Sputter Coater equipped with a Au/Pd (80/20) target and MTM-10 thickness monitor 
was used to coat samples before SEM imaging. SEM micrographs were obtained on glass 
slides, and TEM micrographs were obtained on carbon-coated copper grids. 
Thermogravimetric analysis (TGA) was performed on a Shimadzu TGA-50 equipped with a 
platinum pan, and samples were heated at a rate of 3°C/min under air. Size and zeta potential 
information was obtained on a Malvern ZetaSizer dynamic light scattering instrument. 
Fluorescence spectra were obtained on a Shimadzu RF-530PC spectrofluorophotometer. 
Confocal microscopic images were obtained on glass slides and imaged on the Olympus 
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FlowView500 confocal microscope at the UNC-CH Microscope and Imaging Facility. 
Images were analyzed using ImageJ (with the UCSD plugin) and PhotoShop.  
4.4.2. Synthesis of Reagents 
Synthesis of DSPE-Peg2K-AA. 4-methoxybenzoic acid (3 g, 20 mmol) in 10 mL 
thionyl chloride was refluxed for 2 h. Remaining thionyl chloride was removed in vacuo to 
give 4-methoxybenzoyl chloride. Under Ar gas, a solution of 4-methoxybenzoyl chloride 
(1.000 g, 5.862 mmol) in 10 mL CH2Cl2 was slowly added to a solution of 
diethylenetriamine (0.588 mL, 5.862 mmol) and 2 mL TEA in 10 mL CH2Cl2 at 0 °C. The 
reaction mixture was stirred for 2 h, and the slurry was diluted with additional CH2Cl2 and 
washed with 1 M NaOH. The organic layer was dried with Na2SO4, and the solvent was 
concentrated under reduced pressure. The residue was purified by silica gel column 
chromatography with CH2Cl2/methanol (5:1, v/v) with 1-2% TEA as the eluent to yield N-(2-
((2-aminoethyl)amino)ethyl)-4-methoxybenzamide. Yield: 20%. 1H NMR (CDCl3): δ 7.79 
(d, 2H), 6.90 (d, 2H), 3.82 (s, 3H), 3.91 (s, 24H), 3.27 (m, 2H), 2.90 (m, 4H), 2.75 (m, 2H). 
N-(2-((2-aminoethyl)amino)ethyl)-4-methoxybenzamide (130 mg, 0.55 mmol) was reacted 
with PEG2K-bis-carboxylate  (1.2 g, 0.55 mmol) in 80 mL anhydrous CH2Cl2 in the presence 
of N,N’-dicyclohexylcarbodiimide (230 mg, 1.1 mmol) and 4-dimethylaminopyridine (135 
mg, 1.1 mmol) under N2 for 48 h. After solvent concentration, 300 mL diethyl ether was 
added to the mixture, and the crude product precipitated out and was isolated by 
centrifugation. The product was purified by silica gel column chromatography with 
CH2Cl2/methanol (10:1 v/v) as the eluent to afford AA-PEG2K-mono-carboxylate. Yield: 
35%.1H NMR (CDCl3): δ 7.77 (m, 2H), 6.89 (d, 2H), 4.20 (m, 2H), 3.95 (s, 3H), 3.81 (t,4H), 
3.61 (s,180H)3.44 (m, 2H). AA-PEG2K-mono-carboxylate (300 mg, 0.13 mmol) was reacted 
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with DSPE (115 mg, 0.15 mmol) in 25 mL anhydrous CH2Cl2 in the presence of N,N’-
dicyclohexylcarbodiimide (53 mg, 0.26mmol) and 4-dimethylaminopyridine (31.3 mg, 0.26 
mmol) under N2 for 48 h. After solvent concentration, 50 mL diethyl ether was added to the 
mixture, and the crude product precipitated out and was isolated by centrifugation. The 
product was then purified by silica gel column chromatography with CH2Cl2/methanol (10:1 
v/v) as the eluent to afford AA-PEG2K-DSPE. Yield: 30%.1H NMR (CDCl3): δ 7.78 (m, 2H), 
6.88 (d, 2H), 4.22 (m, 4H), 3.81 (s, 3H), 3.62 (s, 180H), 2.25 (s, 6H), 1.57 (s, 10H), 1.23 (S, 
30H), 0.85 (t, 6H). 
4.4.3. Synthesis of DSCP- and Suc-Containing NCPs 
 
Synthesis of Mg-DSCP NCP.  Particles of Mg-DSCP were prepared by a methanol-
induced nanoprecipitation technique. In a 50 mL round bottom flask, 125 µL 0.25 M methyl 
ammonium DSCP (18.6 mg, 0.0313 mmol) and 188 µL 0.2 M MgCl2·6H2O (7.64 mg, 0.0376 
mmol) were combined in 4.685 mL H2O. Stirring rapidly, ~30 mL methanol was poured into 
the H2O solution, resulting in a white dispersion which was stirred at room temperature for 1 
h, in the dark. The particles were isolated by centrifugation at 13,000 rpm for 15 min, washed 
and centrifuged once with EtOH, and dispersed in EtOH. Yield = 3.5 mg (43.0 %). 
Synthesis of Mn-DSCP NCPs.  Particles of Mn-DSCP were first prepared by a 
methanol-induced nanoprecipitation technique. In a 50 mL round bottom flask, 125 µL 0.25 
M aq. methyl ammonium DSCP (18.6 mg, 0.0313 mmol) and 188 µL 0.2 M aq. MnCl2·4H2O 
(7.44 mg, 0.0376 mmol) were combined in 4.685 mL H2O. Stirring rapidly, ~30 mL 
methanol was poured into the H2O solution, resulting in a white dispersion which was stirred 
at room temperature for 1 h, in the dark. The particles were isolated by centrifugation at 
13,000 rpm for 15 min, washed and centrifuged twice with EtOH, and dispersed in EtOH.  
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Additionally, a surfactant-templated heating technique resulted in particles of Mn-
DSCP. Two reverse (water in oil) microemulsions were prepared by two 50 mL round 
bottom flasks receiving 10 mL 0.5 M 1-hexanol in isooctanes and 365 mg CTAB (for 0.1 M 
CTAB). One flask was given (while stirring) 90 µL 0.2 M (9.58 mg, 0.018 mmol) aq. 
methylammonium DSCP. The other flask was given 90 µL 0.2 M (4.21 mg, 0.018 mmol) aq. 
MnCl2·6H2O. Both reverse microemulsions (W = 10) became clear instantly, were combined 
in a microwave vessel, and microwaved at 120 ºC for 10 min using 400 W and 100% power. 
The product was isolated by centrifugation, subsequently washed and centrifuged once with 
EtOH, and dispersed in EtOH.  
 Synthesis of Larger Zr-DSCP NCP. Larger NCPs of Zr-DSCP were synthesized by 
a solvothermal method. In a 20 mL glass vial, 59.6 mg (0.1116 mmol) DSCP and 26.7 mg 
(0.1146 mmol) ZrCl4 were dissolved in 10 mL DMF containing 200 µL 3M (0.6 mmol, 5 
eq.) acetic acid. The vial was capped and placed in a 60 ºC oven overnight (18 h). The 
resulting white dispersion was isolated by centrifugation and were subsequently washed (by 
sonication) and centrifuged twice with ethanol. The particles were dispersed in ethanol Yield: 
30 mg (34.8 %). 
 Solvothermal Microwave Synthesis of Smaller Zr-DSCP NCP. ZrCl4 (12.56 mg, 
0.0539 mmol) and DSCP (26.95 mg, 0.0505 mmol) were dissolved in 10 mL DMF with the 
addition of 83 µL 3 M (0.25 mmol) acetic acid aq., and the solution was heated in a sealed 
microwave vessel at 60 °C for 20 min without stirring. The product was isolated from the 
resulting white dispersion by centrifugation at 13,000 rpm for 15 min, washed by sonication 
and centrifugation once each with DMF and H2O, and dispersed in EtOH. 
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Synthesis of Smaller Zr-DSCP NCP. NCPs of DOPA-capped Zr-DSCP were 
prepared by an acetone-induced precipitation technique. In a 150 mL beaker, 34.8 mg 
(0.1493 mmol) ZrCl4 was dissolved in 13.5 mL DMF, followed by the addition of 80.4 mg 
(0.1505 mmol) DSCP and 270 µL 3M (0.75 mmol, 5 eq.) acetic acid. Stirring rapidly, ~100 
mL acetone was poured into the DMF solution, resulting in a white dispersion which was 
stirred at room temperature for 1 h, in the dark. The particles were isolated by centrifugation 
and underwent subsequent washes/centrifugation once with acetone and once with ethanol. 
The particles were dispersed in ethanol. Yield: 24 mg (21.0 %).  
Synthesis of DOPA-Capped Zr-DSCP NCP. Particles of DOPA-capped Zr-DSCP 
NCP were prepared by a chloroform-induced precipitation technique. ZrCl4 (17.4 mg, 0.0747 
mmol) was dissolved in 6.25 mL DMF, followed by the addition of 40.2 mg (0.0753 mmol) 
DSCP and 135 µL 3M (0.405 mmol, 5 eq.) acetic acid. A separate solution of CHCl3 
containing 2.4 mg (3.32 µmol) DOPA was prepared. Stirring rapidly, the reaction slurry was 
precipitated with the DOPA solution, resulting in a white dispersion which was stirred at 
room temperature for 1 h, in the dark. The particles were isolated by centrifugation, 
subsequently washed/centrifuged twice with ethanol, and dispersed in ethanol. Yield: 22 mg 
(38.1 %). 
Synthesis of La-DSCP NCP. Particles of La-DSCP NCP were prepared by a 
surfactant-assisted heating method. Two reverse (water in oil) microemulsions were prepared 
by two 25 mL round bottom flasks receiving 5 mL 0.3 M TritonX-100/1.5 M 1-hexanol in 
cyclohexane. One flask was given (while stirring) 200 µL 25 mg/mL (5 mg, 0.0135 mmol) 
aq. LaCl3·7H2O pH = 5.5. The other flask was given 200 µL 25 mg/mL (5 mg, 0.00936 
mmol) aq. DSCP pH = 4 and 30 µL 200 mg/mL (6 mg, 0.0083 mmol) DOPA in CHCl3. Both 
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reverse microemulsions (W = 7.4) became clear instantly, were combined in a microwave 
vessel, and microwaved at 70 ºC for 10 min using 400 W, 100% power, and a 5 min ramping 
time. The white product was isolated by centrifugation, subsequently washed/centrifuged 
once with THF, and dispersed in THF. Yield: 13.5 mg (84.4 %).  
 Synthesis of La-Suc NCP. Particles of La-Suc were prepared by a surfactant-
assisted heating method. Two reverse (water in oil) microemulsions were prepared by two 25 
mL round bottom flasks receiving 5 mL 0.3 M TritonX-100/1.5 M 1-hexanol in cyclohexane. 
One flask was given (while stirring) 200 µL 25 mg/mL (5 mg, 0.0135 mmol) aq. LaCl3·7H2O 
pH = 5.5. The other flask was given 200 µL 50 mg/mL (10 mg, 0.037 mmol) aq. succinic 
acid (Na2(suc)·6H2O) pH = 6 and 30 µL 200 mg/mL (6 mg, 0.0083 mmol) DOPA in CHCl3. 
Both reverse microemulsions (W = 7.4) were combined in a microwave vessel, and 
microwaved at 70 ºC for 10 min using 400 W, 100% power, and a 5 min ramping time. The 
white product was isolated by centrifugation, subsequently washed and centrifuged once with 
THF, and dispersed in THF. Yield: 13.5 mg (64.3 %).  
Synthesis of Ru(bpy)32+-doped La-DSCP. Particles of La-Suc doped with 
Ru(bpy)32+ were prepared by a surfactant-templated method in which two reverse (water in 
oil) microemulsions were made by two 25 mL round bottom flasks receiving 5 mL 0.3 M 
TritonX-100/1.5 M 1-hexanol in cyclohexane. One flask was given (while stirring) 200 µL 
25 mg/mL (5 mg, 0.0135 mmol) aq. LaCl3·7H2O pH = 5.5. The other flask was given 200 µL 
50 mg/mL (10 mg, 0.037 mmol) aq. succinic acid (Na2(suc)·6H2O) pH = 6, 30 µL 200 
mg/mL (6 mg, 0.0083 mmol) DOPA in CHCl3, and 48 µL 50 mg/mL (2.4 mg, 0.0037 mmol) 
[Ru(5,5’-CO2H-bpy)(bpy)2](PF6)2. The Ru(bpy)32+ derivative was synthesized by a previous 
method.1 Both reverse microemulsions (W = 7.4) became clear instantly, were combined in a 
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microwave vessel, and microwaved at 70 ºC for 10 min using 400 W, 100% power, and a 5 
min ramping time. The orange product was isolated by centrifugation, subsequently 
washed/centrifuged once with THF, and dispersed in THF. Yield: 1.7 mg (8.5 %). 
 4.4.4. Surface Modifications of Zr-DSCP NCP 
 
Synthesis of PVP-Coated Zr-DSCP NCP. A total of 8 mg of Zr-DSCP was isolated 
by centrifugation and dispersed by sonication in 8 mL ethanol (for 1 mg/mL particles). 
Molecular weight 23K polyvinylpyrollidone (PVP) (8.5 mg, 0.37 µmol) was added and the 
dispersion was stirred at room temperature 18 h, in the dark. The resulting particles of Zr-
DSCP@PVP were isolated by centrifugation, subsequently washed and centrifuged twice 
with ethanol, and redispersed in ethanol. Yield: 5 mg (62.5 %).  
Silica Coating of PVP-Coated Zr-DSCP NCP. Silica coating of Zr-DSCP@PVP 
was carried out by isolating 6.6 mg Zr-DSCP@PVP by centrifugation and dispersing in 
3.025 mL ethanol. A basic ethanol solution was prepared by adding 275 µL concentrated 
NH4OH to 13.2 mL ethanol. While stirring, the particle dispersion was added to the basic 
ethanol solution, followed by the addition of 26.5 µL tetraethyl orthosilicate (TEOS). The 
dispersion was stirred at room temperature for 4 h, in the dark. This procedure was carried 
out such that there was 0.4 mg/mL Zr-DSCP@PVP, 0.25 M NH4OH, and 4 µL TEOS per mg 
Zr-DSCP@PVP. The resulting particles were isolated by centrifugation, subsequently 
washed/centrifuged twice with ethanol, and dispersed in ethanol. Yield: 5.8 mg (87.5 %).  
4.4.5. Lipid Coating Procedures 
 
Lipid Coating of Zr-DSCP or La-DSCP NCP. Particles of Zr-DSCP or La-DSCP 
(0.5 mg) were isolated by centrifugation and dispersed in 100 µL THF. All lipid solutions (5 
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mg/mL in THF) and the particle dispersion were heated to 50 ºC in a water bath. The 
following lipids were added to the particle dispersion: 42 µL (0.21 mg, 0.543 µmol) 
cholesterol, 84 µL (0.42 mg, 0.543 µmol) DOPC, and 150 µL (0.75 mg, 0.273 µmol, 20 
mol%) DSPE-Peg2K. A solution of EtOH/H2O (30 % v/v, 500 µL) was heated to 50 ºC, and, 
while stirring, the particle dispersion was added dropwise. THF was removed by an N2 
stream.  
Lipid Coating and Anisamide-Targeting of La-DSCP or La-Suc NCP. Particles of 
La-DSCP or La-Suc (0.5 mg) were isolated by centrifugation and dispersed in 100 µL THF. 
All lipid solutions (5 mg/mL in THF) and the particle dispersion were heated to 50 ºC in a 
water bath. The following lipids were added to the particle dispersion: 42 µL (0.21 mg, 0.543 
µmol) cholesterol, 84 µL (0.42 mg, 0.543 µmol) DOPC, 135 µL (0.675 mg, 0.245 µmol) 
DSPE-Peg2K, and 15 µL (0.075 mg, 0.025 µmol) DSPE-Peg2K-AA. A solution of EtOH/H2O 
(30 % v/v, 500 µL) was heated to 50 ºC, and, while stirring, the particle dispersion was added 
dropwise. THF was removed by an N2 stream.  
Release Profiles. All release profiles were carried out in 5 mM PBS at 37 ºC. A 1 L 
solution of 5 mM PBS was prepared by dissolving 8.528 g (0.146 mol) NaCl and 680 mg (5 
mmol) KH2PO4 in 500 mL MilliQ H2O. The pH was adjusted to 7.4 with NaOH, and the 
solution was brought to 1 L with MilliQ H2O. Between 2-4 mg DSCP-containing NCPs were 
prepared in 500 µL PBS or 30 % v/v EtOH/H2O and added to a length of 10K molecular 
weight cutoff dialysis tubing. The dialysis tubing was submerged in a beaker containing 400 
mL 5 mM PBS stirring at 37 ºC. Aliquots of 1 mL each were removed from the beaker at 
designated time intervals, and the volumes were replaced with fresh PBS. Samples were 
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digested in 115 µL concentrated HNO3, filtered through a 0.2 µM PTFE syringe filter, and 
analyzed by ICP-MS for Pt content. Pt content (in ppb) was converted to % drug released. 
4.4.6. In Vitro Assay Methods 
 
Cell Lines. NCI-H460 non-small cell lung cancer cells (ATCC# HTB-177) and A549 
non-small cell lung cancer cells (ATCC# CCL-185) were purchased from the Tissue Culture 
Facility of Lineberger Comprehensive Cancer Center at the University of North Carolina at 
Chapel Hill. Both cell lines were maintained in RPMI-1640 growth medium supplemented 
with 10% FBS and 2% penicillin-streptomycin. 
Cytotoxicity Assays of Zr-DSCP NCPs Against NCI-H460 Cells. Confluent NCI-
H460 cells were trypsinized and counted by hemocytometer. Cells were plated in 6-well 
plates at a cell density of 5 x 104 cells/well in 3 mL RPMI-1640 complete growth medium. 
The cells were incubated at 37 °C and 5% CO2 overnight. Cisplatin and a particle dispersion 
of large Zr-DSCP in RPMI-1640 media and additional media were added to wells, resulting 
in cisplatin concentrations (µM) of 0, 2.5, 5, 10, 30, and 80. Cells were incubated (37 °C, 5% 
CO2) for 72 h. Viability was determined by the trypan blue exclusion assay. 
 Cytotoxicity Assay of La-DSCP NCPs Against NCI-H460 Cells. Confluent NCI-
H460 cells were trypsinized and a cell density was obtained from a hemocytometer. Six-well 
plates were seeded with 5.0x104 cells/well and a total of 3 mL media. Plates were incubated 
at 37°C and 5% CO2 overnight. Amounts of cisplatin or NCP suspensions in RPMI-1640 
medium were added to wells, along with additional media, resulting in various cisplatin 
concentrations (µM). Plates were incubated at 37°C and 5% CO2 for 48 h and viability was 
determined via the trypan blue exclusion assay. 
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 Cytotoxicity Assay of La-DSCP Against A549 Cells. Confluent A549 cells were 
trypsinized and a cell density was obtained from a hemocytometer. Six-well plates were 
seeded with 5.0x104 cells/well and a total of 3 mL media. Plates were incubated at 37°C and 
5% CO2 overnight. Amounts of cisplatin or NCP suspensions in RPMI-1640 medium were 
added to wells, along with additional media, resulting in various cisplatin concentrations 
(µM). Plates were incubated at 37°C and 5% CO2 for 48 h and viability was determined via 
the trypan blue exclusion assay. 
 Viability Assay of La-Suc NCPs Against NCI-H460 Cells. Confluent NCI-H460 
cells were trypsinized and a cell density was obtained from a hemocytometer. Six-well plates 
were seeded with 5.0x104 cells/well and a total of 3 mL media. Plates were incubated at 37°C 
and 5% CO2 overnight. Amounts of NCP suspensions in RPMI-1640 medium were added to 
wells, along with additional media, resulting in various amounts equivalent to µM cisplatin 
concentrations tested in the cytotoxicity assays. Plates were incubated at 37°C and 5% CO2 
for 24 h and viability was determined via the trypan blue exclusion assay. 
 Viability Assay of La-Suc NCPs Against A549 Cells. Confluent A549 cells were 
trypsinized and a cell density was obtained from a hemocytometer. Six-well plates were 
seeded with 5.0x104 cells/well and a total of 3 mL media. Plates were incubated at 37°C and 
5% CO2 overnight. Media was removed from wells, and each well was washed with 2 mL 
PBS. Amounts of NCP suspensions in RPMI-1640 medium were added to wells, along with 
additional media, resulting in various amounts equivalent to µM cisplatin concentrations 
tested in the cytotoxicity assays. Plates were incubated at 37°C and 5% CO2 for 24 h and 
viability was determined via the trypan blue exclusion assay. 
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 Viability Assay of LaCl3 Salt Against NCI-H460 and A549 Cells. Either confluent 
NCI-H460 or A549 cells were trypsinized and counted with a hemocytometer. Six-well 
plates were seeded with 5.0x104 cells/well and a total of 3 mL media/well. Plates were 
incubated at 37 °C and 5 % CO2 overnight. Media was removed from wells, and each well 
was washed with 2 mL PBS. Amounts of LaCl3·7H2O dissolved in media were added to the 
wells, followed by additional media, resulting in amounts equivalent to that given with La 
contained in NCP in cytotoxicity assays. Plates were incubated at 37 °C with 5 % CO2 for 48 
h, and viability was determined via the trypan blue exclusion assay. 
 Confocal Microscopy Using NCI-H460 Cells. Confluent NCI-H460 cells were 
trypsinized and counted with a hemocytometer. Glass coverslips were placed in the wells of 
six-well plates, followed by 2.0x105 cells/well and a total of 3 mL media/well. Plates were 
incubated at 37 °C and 5 % CO2 overnight. Media was removed from wells, and each well 
was washed with 2 mL PBS. Amounts of Ru(bpy)32+-doped La-Suc NCPs (0.2 mg/well) 
were added with a total of 2 mL media/well. Wells were incubated at 37 °C and 5 % CO2 for 
30 min, media removed, wells washed with 1 mL PBS, and coverslips adhered onto glass 
slides with antifade mounting medium. Images were obtained on an Olympus FlowView500 
confocal microscope. 
 Competitive Binding Assays Using NCI-H460 Cells. Confluent NCI-H460 cells 
were trypsinized and counted with a hemocytometer. Five T25 culture flasks were seeded 
with 1x106 cells/flask and 6 mL of complete growth medium. The flasks were incubated at 
37 °C and 5 % CO2 for three days, changing the media once during this time. Media was 
removed from the flasks, and each flask was washed with 2 mL PBS. The flasks were given 
3 mL media containing different amounts of NH3-PEG5K-AA and incubated for 30 min. The 
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media was removed, each flask washed with 2 mL PBS, and 0.5 mg La-DSCP NCPs were 
added to each flask with a total of 6 mL media. The flasks were incubated for 30 min, 
trypsinized, and cell pellets were digested in concentrated HNO3 for 2 days. Samples were 
diluted with H2O for a total of 4 mL 2% HNO3 and analyzed by ICP-MS for La and Pt 
content. 
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CHAPTER 5 
 
Nanoscale Coorination Polymers for Delivery of an Oxaliplatin Analog 
 
 
5.1. Introduction 
 
5.1.1. Platinum Complexes for Cancer Chemotherapy - Oxaliplatin 
 
Platinum-based drugs have played an important role in cancer treatment. Oxaliplatin 
(Figure 5.1) is one of the three FDA-approved platin-based cancer chemotherapeutics 
(approved in 2004) and was approved for the treatment of colorectal cancer alone or in 
combination with 5-fluorouracil.1,2 Additionally, oxaliplatin is undergoing clinical trials for 
the treatment of pancreatic ductal adenocarcinoma, a disease with an extremely low survival 
rate. Oxaliplatin chemotherapy was originally used to treat cisplatin-resistant cancers and 
lower the toxicity profile of platin chemotherapeutics.3-5 Oxaliplatin is adept at treating 
cisplatin-resistant cancers as this agent forms different DNA adducts that are not routinely 
recognized by repair proteins and the accumulation of this agent is less-dependent on copper 
transporters, which contributes to cisplatin resistance. 
 
Figure 5.1. Structure of oxaliplatin, one of the three FDA-approved platin-based 
chemotherapeutics. 
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Even though oxaliplatin therapy does not lead to nephrotoxicity like cisplatin 
treatment, oxaliplatin suffers from the myriad of drawbacks characteristic of conventional 
anticancer agents such as low selectivity, high systemic toxicity, poor pharmacokinetics, and 
narrow therapeutic windows.3 Non-specific distribution of oxaliplatin leads to serious side 
effects such as neurotoxicity and hematologic toxicity. In order to alleviate these drawbacks, 
we propose incorporation of a Pt(IV) oxaliplatin prodrug within an NCP material. 
Nanocarriers for the delivery of oxaliplatin have been reported previously,6,7 but an NCP 
platform for delivery of this agent has never been reported. 
 Herein this chapter, synthesis and characterization of NCPs containing an oxaliplatin 
prodrug are discussed. These NCPs are constructed with different binding metals and the 
oxaliplatin prodrug c,c,t-[PtCl2(DACH)(O2CCH2CH2CO2H)2] (Figure 5.2, DSOX for 
disuccinato oxaliplatin). Synthesis and characterization of all oxaliplatin prodrugs and 
associated complexes is described in the experimental section in their entirety.  
N
H
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Figure 5.2. Structure of disuccinato oxaliplatin (DSOX), an oxaliplatin prodrug. 
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5.2. Results and Discussion 
 
 5.2.1. Synthesis and Characterization of La-DSOX NCP 
 
 NCPs of La-DSOX were prepared by a methanol-induced nanoprecipitation of a 
solution of the methylammonium salt of DSOX and LaCl3·7H2O in H2O adjusted to pH = 
7.25 with NaOH. The resulting material is irregularly-shaped and ~50 nm by SEM (Figure 
5.3). These particles are 5.3 wt% Pt (16.7 wt% DSOX) and 42.7 wt% La by ICP-MS. This 
low drug loading suggests that these particles are primarily La2O3, indicating the need for a 
different synthetic strategy. A reverse microemulsion technique yielded NCPs of La-DSOX 
as well. Aqueous solutions of DSOX and LaCl3·7H2O were placed in a reverse 
microemulsion with the organic phase 0.3 M TritonX-100/1.5 M 1-hexanol in cyclohexane 
and stirred at room temperature for 24 h. The resulting particles are between 150-300 nm by 
SEM (Figure 5.4).  
 
Figure 5.3. SEM micrograph of La-DSOX NCP synthesized by a rapid precipitation 
technique. 
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Figure 5.4. SEM micrographs of La-DSOX synthesized by a reverse microemulsion 
technique. 
 
 5.2.2. Synthesis and Characterization of Nd-DSOX NCP 
 
 NCPs of Nd-DSOX were prepared by a methanol-induced nanoprecipitation of a 
solution of the dimethylammonium salt of DSOX and Nd(NO3)3·6H2O in H2O adjusted to 
pH = 7.0. The resulting particles are irregularly-shaped and ~100 nm in diameter by SEM 
(Figure 5.6). EDS shows the presence of both Pt and Nd (Figure 5.5). Nd-DSOX is 5.2 wt% 
Pt (16.3 wt% DSOX) by ICP-MS. Like with La-DSOX, these NCPs possess lower DSOX 
drug loading than expected, likely due to the formation of La2O3 or Nd2O3 with this method. 
 
Figure 5.5. SEM micrograph of Nd-DSOX NCPs. 
a) b) 
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Figure 5.6. EDS plot of Nd-DSOX NCPs showing the presence of Nd and Pt. 
 
 5.2.3. Synthesis and Characterization of Zr-DSOX NCP 
 
 Particles of Zr-DSOX were prepared by a solvothermal synthesis in which DSOX and 
ZrCl4 were reacted in DMF and acetic acid at 100 °C for 4 h. The resulting particles were 
spherical and between 100-150 nm in diameter by SEM and irregular and slightly fused by 
TEM (Figure 5.7). It is likely that these particles degrade by high energy electrons used in 
TEM imaging studies. The SEM diameter agrees with size data obtained by DLS in EtOH (Z 
average = 116 nm, PDI = 0.271) and H2O (Z average = 121 nm, PDI = 0.260). TGA yields a 
moderate DSOX drug loading, 44.9 wt% (Figure 5.8). 
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Figure 5.7. SEM (a) and TEM (b) micrographs of Zr-DSOX NCPs. 
 
Figure 5.8. TGA plot of Zr-DSOX showing organic weight loss corresponding to 44.9 wt% 
DSOX drug loading. 
 
 
5.3. Conclusion 
 
A Pt(IV) oxaliplatin prodrug was synthesized and incorporated in different NCPs 
using various binding metals. A moderate drug loading was determined for Zr-based NCPs 
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(44.9 wt%). This drug loading, along with a diameter less than 200 nm, make these particles 
promising candidates for further stabilization via lipid encapsulation. 
5.4. Experimental Details 
 
5.4.1. Materials and Methods 
 
All chemicals, unless otherwise noted, were purchased from Fisher Scientific or 
Sigma Aldrich and used without further purification. Scanning electron microscopy (SEM) 
was obtained on a Hitachi 4700 Field Emission Scanning Electron Microscope, and 
transmission electron microscopy (TEM) was obtained on a JEM 100CX-II Transmission 
Electron Microscope. A Cressington 108 Auto Sputter Coater equipped with a Au/Pd (80/20) 
target and MTM-10 thickness monitor was used to coat samples before SEM imaging. SEM 
micrographs were obtained on glass slides, and TEM micrographs were obtained on carbon-
coated copper grids. Thermogravimetric analysis (TGA) was performed on a Shimadzu 
TGA-50 equipped with a platinum pan, and samples were heated at a rate of 3°C/min under 
air. Size and zeta potential information was obtained on a Malvern ZetaSizer dynamic light 
scattering instrument. A Varian 820-MS Inductively Coupled Plasma-Mass Spectrometer 
was used to determine metal contents. Energy dispersive X-ray spectroscopy (EDS) was 
conducted using an Oxford 7200 IncaPentaFET-x3 energy dispersive X-ray spectrometer. 
The EDS data was processed with the Inca Microanalysis Suite. Each EDS sample was 
prepared by placing a drop of an ethanol suspension of the nanomaterial on a strip of carbon 
tape affixed to an aluminum sample holder, and the ethanol was allowed to evaporate. 1H 
NMR spectra were recorded on a Bruker NMR 400 DRX 400 MHz instrument. Infrared 
spectra were obtained of solid powders using a Shimadzu IR Prestige-21 Fourier Transform 
Infrared Spectrophotometer. 
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5.4.2. Synthesis of Pt(IV) Oxaliplatin Prodrugs and Related Complexes 
 
Synthesis of Pt(DACH)Cl2.  
 
Pt(DACH)Cl2 was synthesized using an established method.8 Potassium 
tetrachloroplatinate, K2PtCl4, (1 g, 2.4 mmol) was dissolved in 40 mL H2O, followed by the 
addition of 1.690 g (10.2 mmol) KI dissolved in 6 mL H2O which instantly led to the 
formation of a violet solution. R,R-diamminocyclohexane (DACH, 490 mg, 4.2 mmol) 
dissolved in 6 mL H2O was added dropwise, resulting in formation of a yellow precipitate 
which was stirred at room temperature for 24 h. The precipitate, Pt(DACH)I2, was filtered 
and washed with H2O and acetone and dried under vacuum. Yield: 78.2%. 1H NMR (DMSO-
d6): δ (ppm), 1.030 (m, 2H); 1.241 (m, 2H); 1.467 (m, 2H); 1.934 (m, 2H); 2.354 (m, 2H). 
IR: ῦ = 3280, 3200 (υN-H); 3020, 2960 (υC-H); 1640 (υC-N). Pt(DACH)I2 (1 g, 1.9 mmol) was 
suspended in 30 mL H2O, followed by the addition of 650 mg (3.9 mmol) AgNO3, which led 
to the instant formation of Pt(DACH)(H2O)22+ and AgI. The dispersion was stirred at room 
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temperature for 24 h, and AgI removed by filtration. While stirring, excess NaCl was added 
to the filtrate, resulting in the formation of the bright yellow Pt(DACH)Cl2 product which 
was filtered, washed with H2O and acetone, and allowed dried under vacuum. Yield = 91.8%. 
IR: ῦ = 3320, 3200 (υN-H); 2960, 2880 (υC-H); 1560 (υC-N). TGA: 46.7 wt% organic loss, 
theoretical = 48.7 wt%. 
Synthesis and Characterization of Pt(DACH)Cl2(OH)2. 
 
  Pt(DACH)Cl2 (730 mg, 1.9 mmol) was suspended in 50 mL H2O, followed by the 
addition of 7 mL 30% H2O2/H2O. The slurry was heated to 70 °C and stirred at this 
temperature for 24 h. The light yellow product, Pt(DACH)Cl2(OH)2, was filtered and washed 
with H2O and acetone. Yield = 64.7%. 1H NMR (DMSO-d6): δ (ppm), 1.054 (m, 2H); 1.235 
(m, 2H); 1.471 (m, 2H); 1.838 (m, 2H); 2.077 (m, 2H). IR: ῦ = 3495 (υO-H); 3105 (υN-H); 
2925, 2865 (υC-H); 1580 (υC-N). 
 Synthesis and Characterization of Pt(DACH)Cl2(OH)2(suc)2. 
 
Pt(DACH)Cl2(OH)2 (100 mg, 0.24 mmol) and succinic anhydride (52 mg, 0.52 
mmol) were suspended in 2 mL anhydrous DMSO and heated at 70 °C for 48 h under Ar. 
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DMSO was removed by lyophilization, and the resulting brown product, 
Pt(DACH)Cl2(OH)2(suc)2, was washed with acetone and Et2O and dried under vacuum. 
Yield = 50.3%. 1H NMR (DMSO-d6): δ (ppm), 0.896 (m, 2H); 1.233 (m, 2H); 1.421 (m, 2H); 
1.838 (m, 2H); 2.073 (m, 2H); 2.382 (m, 2H); 2.495 (m, 2H). IR: ῦ = 3280 (υN-H); 2960, 2880 
(υC-H); 1680 (υC=O); 1540 (υC-N). TGA: step 1 (125-215 °C, (suc)2Cl2) 50.5 wt%, calculated = 
49.6 wt%; step 2 (215-400 °C, DACH) 25.5 wt%, calculated = 18.6 wt%. 
Synthesis and Characterization of Pt(DACH)Cl2(OH)(OEt).  
 
This complex was not used in the synthesis of DSOX-containing NCPs, but may be 
used for future drug delivery materials. Pt(DACH)Cl2 (200 mg, 0.53 mmol) was suspended 
in 30 mL EtOH, followed by the addition of 10 mL 30% H2O2/H2O. The slurry was heated at 
70 °C for 24 h. The white product, Pt(DACH)Cl2(OH)(OEt), was filtered and dried under 
vacuum. Yield = 57.5%. 1H NMR (DMSO-d6): δ (ppm), 0.750 (m, 2H); 1.150 (t, 2H); 1.235 
(m, 2H); 1.490 (q, 3H); 1.357 (m, 2H); 1.800 (m, 2H); 2.051 (m, 2H). IR: ῦ = 3480 (υO-H); 
3080 (υN-H); 2920, 2880 (υC-H); 1560 (υC-N); 1040 (υC-O). TGA: 51.0 wt% organic loss, 
theoretical = 48.7 wt% 
Synthesis and Characterization of Pt(DACH)Cl2(OEt)(Suc). 
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 This complex was not used in the synthesis of DSOX-containing NCPs, but may be 
used for future drug delivery materials. Pt(DACH)Cl2(OH)(OEt) (125 mg, 0.29 mmol) and 
succinic anhydride (33 mg, 0.33 mmol) were dissolved in 2.5 mL anhydrous DMSO and 
reacted at 70 °C for 48 h. DMSO was removed by lyophilization, and the brown product, 
Pt(DACH)Cl2(OEt)(Suc), was washed with EtOH and dried under vacuum. Yield = 27.9%. 
1H NMR (DMSO-d6): δ (ppm), 0.857 (m, 2H); 1.063 (m, 2H); 1.350 (t, 3H); 1.511 (m, 2H); 
1.939 (m, 2H); 2.089 (m, 2H); 2.315 (m, 2H); 2.410 (m, 2H).  
Synthesis and Characterization of Oxaliplatin. 
 
Oxaliplatin was synthesized as the comparison free drug for any in vitro cytotoxicity 
studies. Pt(DACH)Cl2 (60 mg, 0.16 mmol) was suspended in 5 mL H2O followed by the 
addition of 52 mg (0.31 mmol) AgNO3, resulting in the formation of Pt(DACH)(H2O)22+ and 
AgCl. The slurry was stirred at room temperature for 24 h. AgCl was removed by filtration, 
and 13 mg (0.11 mmol) oxalic acid dissolved in 300 µL 1 M NaOH (0.3 mmol) was added to 
the filtrate and stirred at room temperature for 24 h. The volume was reduced by rotary 
evaporation and white crystals of oxaliplatin formed upon cooling at 4 °C for several hours. 
The crystals were washed with H2O and Et2O and dried under vacuum. IR: ῦ = 3120 (υN-H); 
2950, 2915 (υC-H); 1710, 1670 (υC=O); 1380 (υC-O).       
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5.4.3. Synthesis of Oxaliplatin-Based NCPs 
 
Synthesis of La-DSOX NCPs. Particles of La-DSOX were prepared by a methanol-
induced nanoprecipitation: 750 µL 10 mM (4.9 mg, 0.0075 mmol) DSOX methylammonium 
salt and 75 µL 0.2 M (5.6 mg, 0.015 mmol) LaCl3·7H2O was added to 675 µL H2O. The pH 
of the solution was adjusted to 7.25, and, stirring rapidly, 6 mL methanol was added, 
resulting in the formation of a white dispersion which was stirred for 1 h. The particles were 
isolated by centrifugation, subsequently washed and centrifuged with MeOH and dispersed in 
MeOH. Yield = 1.1 mg (15.7%). 
A different synthesis of La-DSOX was applied as well using a reverse microemulsion 
synthesis. Two reverse (water in oil) microemulsions were prepared by two 50 mL round 
bottom flasks receiving 23.6 mL 0.3 M TritonX-100/1.5 M 1-hexanol in cyclohexane. One 
flask was given (while stirring) 1.255 H2O containing 3.2 mg (0.0052 mmol) DSOX pH = 
7.5. The other flask was given 12.5 µL 0.2 M (0.9 mg, 0.0025 mmol) aq. LaCl3·7H2O. Both 
reverse microemulsions became clear instantly, were combined (W = 10) and stirred at room 
temperature for 24 h. The reaction was quenched with ~15 mL EtOH. The product was 
isolated by centrifugation, subsequently washed and centrifuged twice with EtOH, and 
dispersed in EtOH. 
Synthesis of Nd-DSOX NCPs. Particles of Nd-DSOX were prepared by a methanol-
induced nanoprecipitation: 38 µL 0.2 M (4.9 mg, 0.0075 mmol) DSOX methylammonium 
salt and 75 µL 0.2 M (6.6 mg, 0.015 mmol) Nd(NO3)3·6H2O was added to 1.385 mL H2O. 
The pH of the solution was adjusted to 7.0, and, stirring rapidly, 14 mL methanol was added, 
resulting in the formation of a white dispersion which was stirred for 1 h. The particles were 
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isolated by centrifugation, subsequently washed and centrifuged with MeOH and dispersed in 
MeOH. Yield = 6.0 mg (85.0%). 
Synthesis of Zr-DSOX NCPs.  Particles of Zr-DSOX were synthesized by a 
solvothermal method. In a 20 mL glass vial, 52.6 mg (0.0856 mmol) DSOX and 22.4 mg 
(0.0962 mmol) ZrCl4 were dissolved in 10 mL DMF containing 150 µL 3M (0.45 mmol) 
acetic acid. The vial was capped and placed in a 100 ºC oven for 4 h. The resulting brown 
dispersion was isolated by centrifugation and were subsequently washed (by sonication) and 
centrifuged once each with DMF, H2O, and ethanol. The particles were dispersed in ethanol 
Yield: 3.1 mg (48.0 %). 
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